Page last updated: 2024-08-17

levodopa and Disease Exacerbation

levodopa has been researched along with Disease Exacerbation in 358 studies

Research

Studies (358)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	52 (14.53)	18.2507
2000's	157 (43.85)	29.6817
2010's	117 (32.68)	24.3611
2020's	32 (8.94)	2.80

Authors

Authors	Studies
Gilmour, TP; Handly, E; Iyer, V; Kunselman, AR; Lieu, CA; Savaliya, S; Subramanian, T; Venkiteswaran, K	1
Gao, L; González-Rodríguez, P; Guzman, JN; Ilijic, E; Kaplitt, MG; López-Barneo, J; Schumacker, PT; Stavarache, MA; Stout, KA; Surmeier, DJ; Tkatch, T; Wokosin, DL; Yang, B; Zampese, E	1
Larson, D; Simuni, T	1
Bhidayasiri, R; Phokaewvarangkul, O; Virameteekul, S	1
Kotagiri, YG; Litvan, I; Longardner, K; Mahato, K; Moon, JM; Podhajny, T; Sempionatto, JR; Tehrani, F; Teymourian, H; Wang, J	1
Byran, G; Gangadharappa, HV; Garikapati, KK; Krishnamurthy, PT; Kumari, M; Sola, P	1
Barbosa, ER; Barbosa, PM; Chien, HF; Limongi, JCP; Torres, MRC	1
Bubb, VJ; Kõks, S; Pfaff, AL; Quinn, JP; Singleton, LM	1
Ayton, S; Behnke, S; Berg, D; Bloem, BR; Bordet, R; Bush, AI; Cabantchik, I; Carpentier, J; Chupin, M; Coelho, MVS; Compta, Y; Corvol, JC; de Bie, RMA; Defebvre, L; Deplanque, D; Devedjian, JC; Devos, D; Dexter, DT; Dodel, R; Duce, JA; Duhamel, A; Dušek, P; Eusebio, A; Ferreira, J; Fradette, C; Gago, M; Garçon, G; Guyon Delannoy, P; Habert, MO; Januario, C; Kuchcinski, G; Kulisevsky, J; Labreuche, J; Leclercq, C; Lehericy, S; Lopes, R; Maetzler, W; Mangin, JF; Marques, AR; Meissner, WG; Moreau, C; Nyholm, D; Ory-Magne, F; Otto, M; Ouk, T; Pavese, N; Pigny, P; Poewe, W; Post, B; Potey, C; Pruvo, JP; Rascol, O; Rolland, AS; Růžička, E; Scherfler, C; Seppi, K; Simonin, O; Spino, M; Thobois, S; Tranchant, C; Tricta, F; Viard, R; Vilas, D; Walter, U; Worth, P	1
Colon-Semenza, C; Earp, JE; LoBuono, DL	1
Angelopoulou, E; Bougea, A; Chrysovitsanou, C; Koros, C; Panagiotounakou, E; Papagiannakis, N; Simitsi, AM; Stefanis, L	1
Shih, LC; Wang, R	1
Ben-Ami, E; Djaldetti, R; Franken, L; Kreitman, R; Raveh, E; Reiner, J; Rosset, I	1
Manalo, RVM	1
Abreu, D; Coelho, M; Fabbri, M; Ferreira, JJ	1
Mochizuki, H	1
Isaacson, SH	1
Armstrong, MJ; Okun, MS	1
Calandra-Buonaura, G; Contin, M; Cortelli, P; Lopane, G; Magosso, E; Ursino, M	1
Akhmetzhanov, V; Houlden, H; Kaishibayeva, G; Kaiyrzhanov, R; Karimova, A; Khaibullin, T; Rizig, M; Sadykova, DZ; Seidinova, Z; Shashkin, C; Taskinbayeva, A; Zharkinbekova, N	1
Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS	1
Fabbri, M; Ferreira, JJ; Kauppila, LA; Rascol, O	1
Bai, CH; Chan, L; Hong, CT	1
Müller, T	3
Akpalu, A; Bonvegna, S; Cereda, E; Cham, M; Cilia, R; Del Sorbo, F; Laryea, R; Obese, V; Oppon, K; Pezzoli, G; Sarfo, FS; Zecchinelli, AL	1
Lévesque, D; Nekka, F; Robaey, P; Ursino, M; Véronneau-Veilleux, F	1
Nekka, F; Robaey, P; Ursino, M; Véronneau-Veilleux, F	1
Isaacson, SH; Pahwa, R	1
Chaudhuri, KR; Jenner, P; Qamar, MA; Urso, D	1
Choudhary, M; Khatri, DK; Singh, SB; Sood, A	1
Carroll, DG; Halli-Tierney, AD; Luker, J	1
Chae, D; Chung, SJ; Lee, PH; Park, K	1
Baik, K; Chung, SJ; Jeong, SH; Jung, JH; Lee, PH; Lee, YH; Sohn, YH; Yoo, HS	1
Fujioka, S; Fukae, J; Hatano, T; Hattori, N; Kashihara, KI; Okuma, Y; Ouma, S; Tsuboi, Y; Yamamoto, S; Yoritaka, A	1
Cao, G; Choi, MR; Del Mauro, JS; Fernández, BE; Gironacci, MM; Kouyoumdzian, NM; Puyó, AM; Rukavina Mikusic, NL; Toblli, JE; Trida, V	1
Amenechi, C; Blum, K; Modestino, EJ; O'Toole, P; Reinhofer, A	1
Kim, JS; Lee, JE; Lee, KS; Oh, YS; Ryu, DW; Yoo, IR	1
Rose, O	1
Amboni, M; Barone, P; Cesarelli, M; Fasano, A; Iavarone, A; Iuppariello, L; Lista, I; Palladino, R; Picillo, M; Rucco, R; Sorrentino, G; Varriale, P; Vitale, C	1
Alty, JE; Clissold, BG; Ding, C; Ganga, G; Kempster, PA; McColl, CD; Nagao, K; Reardon, KA; Schiff, M	1
Hortobágyi, T; Kovács, N; Nagy, F; Tollár, J	1
Baig, F; Bajaj, N; Barber, TR; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hu, MTM; Klein, JC; Lawton, M; Malek, N; May, MT; Morris, HR; Swallow, DMA; Williams, N; Wood, NW	1
Kobayashi, S; Matsuda, N; Ugawa, Y	1
Bay, AA; Corcos, DM; Hackney, ME; Hart, AR; Michael Caudle, W	1
Benninger, D; Di Virgilio, G; Du Pasquier, R; Eskioglou, E; Hirt, L; Kuntzer, T; Michel, P; Novy, J; Rossetti, AO; Rouaud, O; Ryvlin, P; Theaudin, M	1
Bloem, BR; Boel, JA; de Bie, RMA; de Haan, RJ; Deuschl, G; Dijkgraaf, MGW; Lang, AE; Munts, AG; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CVM	1
Morris, GP; Rentsch, P; Stayte, S; Vissel, B	1
Chung, SJ; Lee, HS; Lee, PH; Lee, YH; Sohn, YH; Ye, BS; Yoo, HS	1
Corvol, JC; Mariani, LL	1
Cabrera, LY; Sarva, H; Sidiropoulos, C	1
Caetano, A; Meira, B; Pinto, M; Roque, R	1
Möhr, JD; Müller, T	1
Agid, Y; Cornu, P; Czernecki, V; Grabli, D; Karachi, C; Lau, B; Meier, N; Navarro, S; Schuepbach, M; Serra, G; Vidailhet, M; Welter, ML	1
Bajaj, N; Barker, RA; Ben-Shlomo, Y; Burn, DJ; Foltynie, T; Grosset, DG; Grosset, KA; Hardy, J; Kanavou, S; Lawton, MA; Malek, N; Morris, HR; Pitz, V; Williams, NM; Wood, N	1
Friedman, JH	1
Caspell-Garcia, CJ; Coffey, CS; Espay, AJ; Foster, ED; Uribe, L; Weintraub, D	1
Chung, SJ; Kim, JS; Lee, PH; Lee, YH; Oh, JS; Sohn, YH; Ye, BS; Yoo, HS	1
Takeda, A	1
Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H	1
Ziégler, M	1
Ceballos-Baumann, AO; Fietzek, UM; Schroeteler, FE; Ziegler, K; Zwosta, J	1
Baizabal-Carvallo, JF; Jankovic, J	1
Arcaya, JL; Salazar, U; Silva, EJ; Tejeda, CM; Urdaneta, K; Varela, K	1
Aricò, D; Cosentino, FI; Ferri, R; Pizza, F; Plazzi, G	1
Olanow, CW; Schapira, AH	1
Nyholm, D; Senek, M	1
Goulding, N; Kaufmann, H; Martinez, J; Norcliffe-Kaufmann, L; Palma, JA; Roncevic, D	1
Barbui, C; Bovi, T; Cannas, A; Ceravolo, R; Cipriani, A; Dallocchio, C; Di Stefano, A; Frosini, D; Luca, A; Marrosu, F; Matinella, A; Minafra, B; Morgante, F; Morgante, L; Nicoletti, A; Pacchetti, C; Rossi, S; Sciarretta, M; Solla, P; Tinazzi, M; Ulivelli, M; Zappia, M	1
Benecke, R; Walter, U; Wittstock, M; Wolters, A	1
Cáceres-Redondo, MT; Carballo, M; Carrillo, F; Huertas-Fernández, I; Lama, MJ; Mir, P; Vargas-González, L	1
Bendlin, BB; Buyan-Dent, L; Christian, BT; DeJesus, OT; Gallagher, CL; Harding, SJ; Holden, JE; Li, CT; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Stone, CK	1
Adjei, P; Akassi, J; Akpalu, A; Amboni, M; Bonetti, A; Cereda, E; Cham, M; Cilia, R; Fabbri, M; Pezzoli, G; Sarfo, FS	1
Borgohain, R; Jabeen, SA; Kandadai, RM; Kanikannan, MA	1
Halliday, GM; Lewis, SJ; McCann, H; McGeachie, AB; Silberstein, P	1
Chen, Z; Dragan, EM; Ondo, WG	1
Alexiou, A; Psiha, M; Vlamos, P	1
Di Luca, M; Gardoni, F	1
Burn, DJ; Galna, B; Lord, S; Rochester, L	1
Baracchi, F; Bassetti, CL; Galati, S; Kaelin-Lang, A; Möller, JC; Pace, M; Salvadè, A; Sarasso, S; Städler, C; Stanzione, P	1
Carro, J; Gómez Íñiguez, C; López, DE; López-Alburquerque, T; Martínez-Sánchez, F; Meilán, JJ; Millian-Morell, L; Pujante Valverde, IM	1
Cavanaugh, JT; Dibble, LE; Earhart, GM; Ellis, TD; Ford, MP; Foreman, KB	1
Pradhan, S; Tandon, R	1
Chiou, SM; Huang, HM; Lin, YC	1
Bastos Lima, A; Cavaco, S; Damásio, J; Fernandes, J; Gonçalves, A; Mendes, A; Moreira, I; Teixeira-Pinto, A; Vila-Chã, N	1
Hietala, M; Kaasinen, V; Kuoppamäki, M	1
Johansson, A; Linder, J; Memedi, M; Nyholm, D; Pålhagen, S; Westin, J; Widner, H; Willows, T	1
Amernik, K; Gołąb-Janowska, M; Honczarenko, K; Nowacki, P; Pawlukowska, W; Rotter, I; Safranow, K	1
Hattori, N; Ishiguro, Y; Kawajiri, S; Noda, K; Okuma, Y; Tomizawa, Y; Tosaka, Y	1
Kim, AR; Ugryumov, MV	1
Altunbaev, RA; Yakovleva, LA; Zalyalova, ZA	1
Bloem, BR; de Bie, RM; de Haan, RJ; Deuschl, G; Dijkgraaf, M; Lang, AE; Post, B; Suwijn, SR; Tissingh, G; van Hilten, JJ; van Laar, T; Verschuur, CV	1
Alves, G; Bjornestad, A; Forsaa, EB; Larsen, JP; Pedersen, KF; Tysnes, OB	1
Altunkaynak, Y; Baybas, S; Dirican, AC; Köksal, A; Mutluay, B; Vieru, E	1
Alty, JE; Clissold, BG; Ding, C; Ganesvaran, G; Kempster, PA; McColl, CD; Reardon, KA; Schiff, M; Srikanth, V	1
Cardoso, F; Lima, LO; Rodrigues-de-Paula, F; Teixeira-Salmela, LF	1
Baston, C; Horak, F; Mancini, M; Rocchi, L	1
Ben El Haj, R; Benomar, A; Bouhouche, A; Bouslam, N; Regragui, W; Skalli, A; Tazi-Ahnini, R; Yahyaoui, M	1
Amboni, M; Barone, P; Erro, R; Moccia, M; Pellecchia, MT; Picillo, M; Santangelo, G; Vitale, C	1
Abu-Arafeh, I; Combe, L	1
Amboni, M; Barone, P; Erro, R; Longo, K; Moccia, M; Pellecchia, MT; Picillo, M; Vitale, C	1
Drew, L	1
Cerroni, R; D'Angelo, V; Fedele, E; Galati, S; Hainsworth, AH; Liguori, C; Olivola, E; Pierantozzi, M; Saviozzi, V; Stefani, A	1
Rajput, AH; Rajput, EF	1
Bianchi, ML; Bono, G; Cantello, R; Comi, C; Cosentino, M; Ferrari, M; Magistrelli, L; Marino, F; Riboldazzi, G	1
Grabli, D	1
Antonini, A; Cossu, G; Mancini, F; Modugno, N; Pilleri, M; Quatrale, R; Sensi, M; Tamma, F; Zibetti, M	1
Bingefors, K; Isacson, D; Kristiansen, IS; Nyholm, D	1
Welsh, M	1
Deleu, D	1
Okuma, Y; Yanagisawa, N	1
Fox, SH; Lang, AE	1
Arntzen, KA; Bekkelund, SI; Lilleng, H	1
Currie, LJ; Frysinger, RC; Harrison, MB; Huss, DS; Patrie, JT; Wooten, GF; Wylie, SA	1
Arabia, G; Bagnato, A; Cascini, GL; Cipullo, S; Condino, F; Messina, D; Morelli, M; Morgante, L; Nicoletti, G; Novellino, F; Paglionico, S; Pugliese, P; Quattrone, A; Salsone, M	1
Csókay, A; Emri, M; Lengyel, Z; Márián, T; Mikecz, P; Trón, L; Valálik, I	1
Kim, DG; Kim, OJ; Koo, YH; Oh, SH	1
Murata, M	2
Ben-Shlomo, Y; Morris, HR; Wickremaratchi, MM	1
Brandauer, E; El-Demerdash, E; Frauscher, B; Gschliesser, V; Högl, B; Kaneider, M; Poewe, W; Rücker, L	1
Brotchie, J; Fitzer-Attas, C	1
Lyons, KE; Pahwa, R	1
Dikshit, M; Husain, M; Khanna, VK; Maheshwari, PK; Nag, D; Seth, PK; Shukla, R; Srimal, RC	1
Aalto, S; Bergman, J; Brück, A; Marttila, R; Rauhala, E; Rinne, JO	1
Bhatia, KP; Davis, MB; Edwards, MJ; Gerhard, A; Hanna, MG; Mir, P; Polke, JM; Schwingenschuh, P; Sweeney, MG; Trender-Gerhard, I; Wood, NW	1
Silver, DE	1
Chan, P; Fang, X; Liu, H; Qin, Z; Sun, F; Zhang, L	1
Berardelli, A; Bloise, M; Colosimo, C; Defazio, G; Fabbrini, G; Suppa, A	1
Racette, BA; Sterling, C; Willis, AW	1
Kieburtz, K	1
Chan, YH; Chong, WL; Halliwell, B; Huang, SH; Lee, CY; Lim, EC; Looi, WF; Quek, AM; Seet, RC; Tan, JJ; Wang, H	1
Galter, D; Hoffer, B; Kehr, J; Larsson, NG; Lindqvist, E; Olson, L; Pernold, K; Yoshitake, T	1
Carr, J; Fine, J; Kies, B	1
Chung, KA; Holford, NH; Nutt, JG	1
Hauser, RA	1
Aeby, A; Blau, N; Burlina, A; de Klerk, JB; de Lonlay, P; de Rijk-van Andel, JF; Donati, MA; Geurtz, B; Grattan-Smith, PJ; Haeussler, M; Hoffmann, GF; Jung, H; Kamsteeg, EJ; Kok, F; Leuzzi, V; Megarbane, A; Monaghan, H; Renier, WO; Rondot, P; Ryan, MM; Seeger, J; Smeitink, JA; Steenbergen-Spanjers, GC; van der Knaap, MS; Verbeek, MM; Wassmer, E; Weschke, B; Wevers, RA; Wijburg, FA; Wilcken, B; Willemsen, MA; Zafeiriou, DI	1
Hayashi, Y; Hozumi, I; Inuzuka, T; Kimura, A; Sakurai, T; Tanaka, Y; Yamada, M	1
Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J	1
Barone, P; Jankovic, J; Kieburtz, K; Lang, AE; Olanow, CW; Poewe, W; Rascol, O; Stocchi, F; Tolosa, E	1
Liu, Z; Ren, T; Song, L; Wu, N; Yang, X; Yuan, W	1
Auh, S; Dang, N; Hallett, M; Jin, SH; Kang, SY; Kida, T; Lopez, GJ; Shamim, EA; Ueki, Y; Wasaka, T	1
Bugalho, P; da Silva, JA; Neto, B	1
Armand, C; Groenendaal, H; Tarrants, ML	1
Arévalo, GG; Chade, A; Gershanik, O; Gleichgerrcht, E; Manes, F; Roca, M; Torralva, T	1
Lozano, AM; Ponce, FA	1
Bernardos, VS; Del Pozo, SV; López, IC; Ruiz, PJ	1
Alterman, R; Martin, C; Tagliati, M	1
Haahr, A; Hall, EO; Kirkevold, M; Ostergaard, K	1
Halliday, GM; Hely, MA; Loy, C; Morris, JG; Reid, WG	1
Barker, RA; Brayne, C; Evans, JR; Foltynie, T; Mason, SL; Robbins, TW; Williams-Gray, CH	1
Arai, H; Doi, N; Hatta, K; Hattori, N; Kamigaichi, R; Kubo, S; Nakamura, H; Nakanishi, A; Usui, C	1
Hazan, D; Siegert, S; Szyper-Kravitz, M	1
Garcia-Ruiz, PJ	1
Ahlskog, JE; Josephs, KA; Klassen, BT; Lee, KH; Matsumoto, JY; Savica, R; Stead, M	1
Balbi, P; Bertotti, G; Boveri, N; Comi, C; Frazzitta, G; Guaglio, G; Maestri, R; Perini, M; Riboldazzi, G; Turla, M; Uccellini, D	1
Chen, B; Feng, T; Liu, P; Wang, YJ; Zhang, X	1
Arbelo, JM; del Val, JL; Sesar, A	1
Herrero, MT; Linazasoro, G; Pagonabarraga, J	1
Ishihara, A; Kihira, K; Kimura, Y; Matsumoto, M; Miyachi, T; Nakamura, T; Ohtsuki, T; Yamawaki, T	1
Jann, MW	1
Chen, JJ	1
Björklund, A; Decressac, M; Lundblad, M; Mattsson, B; Weikop, P	1
Fernandez, HH	1
Brown, P; Day, BL; Lees, AJ; Ling, H; Massey, LA	1
Eidelberg, D; Feigin, A; Niethammer, M	1
Tarsy, D	1
Alegre, M; Alonso-Frech, F; Artieda, J; Guridi, J; López-Azcárate, J; Obeso, JA; Rodríguez-Oroz, MC; Valencia, M	1
Ait Benhaddou, EH; Benjelloun, H; Benomar, A; Lachhab, L; Razine, R; Regragui, W; Yahyaoui, M	1
Afzal, M; Jyoti, S; Khan, S; Naz, F; Shakya, B; Siddique, YH	1
Joutsa, J; Kaasinen, V; Martikainen, K; Vahlberg, T	1
Dunn, E; Espay, AJ; Gallin, E; Li, JY; Litvan, I; Morgante, F; Munhoz, RP; Teive, HA	1
Alty, JE; Clissold, BG; Ganga, G; Kempster, PA; McColl, CD; Reardon, KA; Schiff, M	1
Bousquet, B; Garnier, JP; Ghanem, G; Le Bricon, T; Letellier, S; Morel, P; Stoitchkov, K; Tsankov, N	1
Kondo, T	2
Froberg, J	1
Factor, SA; Jennings, DL; Marek, KL; Molho, ES	1
Sulkava, R	1
Jennings, D; Marek, K; Seibyl, J	2
Bailey, DL; Brooks, DJ; Ito, K; Morrish, PK; Pavese, N; Rakshi, JS; Uema, T	1
Bonnet, AM; Houeto, JL	1
Minagar, A; Shulman, LM; Weiner, WJ	2
Farrer, MJ; Hulihan, M; Hussey, JM; Krygowska-Wajs, A; Tsuboi, Y; Uitti, RJ; Wszolek, ZK	1
Defebvre, L; Degreef, JF; Destee, A; Dujardin, K; Krystkowiak, P	1
Chmura, TA; Diederich, NJ; Goetz, CG; Leurgans, SE; Moore, CG	1
Morrish, PK	1
Brooks, DJ; Davis, M; Hauser, RA; Lang, AE; Nahmias, C; Poewe, WH; Rascol, O; Remy, P; Reske, S; Ribeiro, MJ; Stoessl, AJ; Watts, RL; Whone, AL	1
Bembi, B; Capus, L; Carrozzi, M; Ciana, G; Gioulis, M; Martini, C; Pittis, MG; Sidransky, E; Zambito Marsala, S; Zorzon, M	1
Berger, KB; Dodel, RC; DuChane, J; Köhne-Volland, R; Machat, O; Meyer, D; Oertel, WH; Reuther, M; Siebert, U; Smala, AM; Spottke, EA	1
Agid, Y; Bonifati, V; Bonnet, AM; Brice, A; Broussolle, E; De Michele, G; Destée, A; Durr, A; Fraix, V; Gasparini, F; Gasser, T; Horstink, MW; Lohmann, E; Meco, G; Nicholl, D; Periquet, M; Rascol, O; Raskin, S; Ruberg, M; Teive, H; Verpillat, P; Vidailhet, M; Wood, NW	1
Bordet, R; Destee, A; Devos, D; Guieu, JD; Kroumova, M; Libersa, C; Vodougnon, H	1
Double, K; Gerlach, M; Reichmann, H; Riederer, P	1
Pantelie, CM; Schoenfeld, MA; Schwartz, B	1
Hirato, M; Kita, K; Kondo, T; Okamoto, K; Yuasa, T	1
Bjugstad, K; Breeze, RE; Freed, CR; Leehey, MA; Thompson, L; Zawada, M	1
Brooks, DJ; Frey, KA; Marek, KL; Oakes, D; Paty, D; Prentice, R; Shults, CW; Stoessl, AJ	1
Mitsuyama, Y	1
Nutt, JG	1
Agid, Y; Bonnet, AM; Cornu, P; Duyckaerts, C; Hauw, JJ; Houeto, JL; Jarraya, B	1
Koller, WC; Tse, W	1
Alonso, F; Lanciego, JL; Marin, C; Obeso, JA; Rodriguez-Diaz, M; Rodriguez-Oroz, M; Zamarbide, I	1
Montgomery, EB	1
Bruno, MK; Considine, E; Garraux, G; Gwinn-Hardy, K; Hallett, M; Hanson, M; Johnson, J; Ptacek, L; Ravina, B; Singleton, A	1
Rajput, A; Rajput, AH; Robinson, CA	1
Cokar, O; Dervent, A; Saltik, S; Uludüz, D; Uslu, T	1
Der, TC; Hagner, D; Joyce, JN; Osredkar, T; Renish, L; Reploge, M; Sakakibara, S; Ueda, S	1
Blandini, F; Calandrella, D; Cosentino, M; Fancellu, R; Frigo, G; Lecchini, S; Mangiagalli, A; Marino, F; Martignoni, E; Nappi, G; Pacchetti, C; Rasini, E; Riboldazzi, G; Samuele, A; Tassorelli, C	1
Calne, DB; de la Fuente-Fernández, R; Furtado, S; Huang, Z; Lu, JQ; Ruth, TJ; Sossi, V; Stoessl, AJ	1
Lang, AE; Postuma, RB	1
Nielsen, KK; Stimpel, H; Werdelin, LM; Winge, K	1
Farkas, R; Málly, J; Stone, TW; Tóthfalusi, L	1
Tetrud, J	1
Blau, N; Jung, HH; Schiller, A; Steenbergen, GC; Wevers, RA	1
Fahn, S	2
Jung, SK	1
Hely, MA; Morris, JG; Reid, WG; Trafficante, R	1
Hoffmann, A; Klotz, P; Kraus, PH; Lewe, J; Przuntek, H	1
Fahn, S; Kieburtz, K; Lang, A; Marek, K; Oakes, D; Olanow, CW; Rudolph, A; Shoulson, I; Tanner, C	1
Gentilucci, M; Negrotti, A; Secchi, C	1
Calne, D; Mak, E; Schulzer, M; Stoessl, AJ	1
Lim, E	1
Carta, M; Cenci, MA; Fisone, G; Håkansson, K; Lundblad, M; Usiello, A	1
Mikolenko, I; Skidmore, F; Weiner, W; Weiss, H	1
Morgan, J; Sethi, KD	1
Farrer, MJ; Gosal, D; Hulihan, M; Irvine, GB; Johnston, JA; Kachergus, J; Lincoln, SJ; Lynch, T; Mark Gibson, J; Mata, IF; Ross, OA; Taylor, JP; Toft, M; Wiley, J	1
Baruzzi, A; Contin, M; Montagna, P; Plazzi, G; Provini, F; Vetrugno, R	1
Schapira, AH	1
Iyer, SS; Morgan, JC; Sethi, KD	1
Ransmayr, G	1
Aa Sunde, N; Østergaard, K	1
Agid, Y; Bonnet, AM; Chastan, N; Cornu, P; Czernecki, V; Dormont, D; Hartmann, A; Houeto, JL; Mallet, A; Mallet, L; Maltête, D; Mesnage, V; Navarro, S; Pidoux, B; Schüpbach, WM; Welter, ML	1
Apetauerova, D; Corapi, K; Norregaard, T; O'Herron, S; Scollins, L; Tarsy, D	1
Hägglund, J; Heinonen, E; Kaugesaar, T; Mäki-Ikola, O; Pålhagen, S; Palm, R	1
Bonuccelli, U; Ceravolo, R; Del Dotto, P; Gambaccini, G; Logi, C; Lucetti, C; Murri, L; Rossi, G	1
Esposito, P; Mohr, M; Stilhart, B; Talmant, V; Tranchant, C	1
Chan, PL; Holford, NH; Kieburtz, K; Nutt, JG; Shoulson, I	1
Jain, S; Lo, SE	1
Goetze, O; Kim, JI; Müller, T; Nikodem, AB; Przuntek, H; Schmidt, WE; Woitalla, D	1
Kulkantrakorn, K; Pongchaiyakul, C; Pulkes, T; Tiamkao, S	1
Boon, P; De Bodt, M; De Letter, M; Santens, P; Van Borsel, J	1
Müller, T; Russ, H	1
Goudreau, JL	1
Morris, ME	1
Turnbull, GI	1
Clissold, BG; Kempster, PA; McColl, CD; Reardon, KR; Shiff, M	1
Mash, DC; Papapetropoulos, S	1
Brachet, P; Damier, P; Henry, V; Lescaudron, L; Paillé, V	1
Chan, PL; Holford, NH; Nutt, JG	1
Haeger, DA; Hock, K; Müller, T; Russ, H; Woitalla, D	1
Tan, EK	1
Carvajal-Gonzalez, S; Childs, MA; Emborg, ME; Li, Q; Meglasson, MD; Merchant, K; Opsahl, A; Stephenson, DT; Tengowski, M	1
Giroux, ML	1
Alicock, LM	1
Damier, P; Meyniel, C	1
Holton, J; Kempster, PA; Lees, AJ; Revesz, T; Selikhova, M; Williams, DR	1
Jankovic, J; Stacy, M	1
Benecke, R; Wolters, A	1
Levy, G	1
De Deyn, PP; Hauser, RA; Jon Stoessl, A; Korczyn, AD; Lang, AE; Poewe, W; Rascol, O; Watts, RL	1
di Poggio, AB; Fornai, F; Paparelli, A; Pellegrini, A; Ruggieri, S	1
Colcher, A; Gilman, S; Huang, N; Jankovic, J; Lipp, A; Low, PA; Marshall, FJ; May, S; Novak, P; Ondo, WG; Reich, SG; Sandroni, P; Shults, CW; Sowell, BB; Stern, MB; Tanner, CM; Thomas, RG; Wooten, F	1
Holford, N; Nutt, JG	1
Krogh, K; Laurberg, S; Ostergaard, K; Sabroe, S	1
Halliday, GM; Hardman, CD; Karaconji, T; Murphy, KE	1
Muthane, U; Ragothaman, M	1
Antonini, A; Canesi, M; Isaias, IU; Lopiano, L; Mancini, F; Manfredi, L; Nappi, G; Natuzzi, F; Pacchetti, C; Pezzoli, G; Zangaglia, R; Zibetti, M	1
de Haan, RJ; Post, B; Speelman, JD	1
Destée, A; Fénelon, G; Kreisler, A; Mastain, B; Tison, F	1
Anderson, KE; Fishman, PS; Gruber-Baldini, AL; Reich, SG; Shulman, LM; Vaughan, CG; Weiner, WJ	1
Almeida, KJ; Campos-Sousa, RN; da Silva, BB; Dos Santos, AR; Lopes-Costa, PV	1
Azulay, JP; Bourdeix, I; Durif, F; Rerat, K; Rogez, R; Tranchant, C	1
Caslake, R; Counsell, C; Gordon, JC; Harris, CE; Moore, JN	1
Falk, M; Künig, G; Neubauer, M; Ransmayr, G; Wagner, M	1
Di Rocco, A; Kollmeier, B; Molinari, SP; Yahr, MD	1
Caraceni, T; Fetoni, V; Giovannini, P; Girotti, F; Musicco, M; Scigliano, G; Soliveri, P	1
Battistin, L; Cagnin, A; Chierichetti, F; Dam, M; Fabbri, M; Ferlin, G; Pizzolato, G; Rossato, A	1
Azulay, JP; Blin, O; Mestre, DR; Serratrice, G; van den Brand, CL	1
Bayülkem, B; Bayülkem, K; Erişir, K; Tuncel, A	1
DeCarvalho, GC; Kestle, JR; Li, CS; Tasker, RR	1
Narabayashi, H	2
Akiguchi, I; Fukuyama, H; Imai, T; Kawamura, J; Kimura, J	1
Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R; Triggs, EJ	1
Goto, I; Kanazawa, I; Kowa, H; Kuno, S; Mizuno, Y; Ogawa, N; Tashiro, K; Yanagisawa, N	1
Albani, F; Baruzzi, A; Contin, M; Riva, R	1
Bodis-Wollner, I; Tagliati, M; Yahr, MD	1
Yanagisawa, N	1
Kanazawa, I; Murata, M	1
Hurtig, HI	1
Schulzer, M	1
Alessandri, A; Bonifati, V; Giustini, P; Meco, G	1
Bioulac, B; Boraud, T; Gross, C; Guehl, D; Julien, J; Rougier, A	1
Bezard, E; Bioulac, B; Deloire, X; Gross, CE; Imbert, C	1
Arnold, G; Gasser, T; Künig, G; Oertel, WH; Pogarell, O; Schwarz, J; Tatsch, K	1
Brooks, DJ; Brunt, ER; Korczyn, AD; Poewe, WH; Rascol, O; Stocchi, F	1
Fariello, RG	1
Colosimo, C; Hughes, AJ; Lees, AJ; Merello, M; Sieradzan, K	1
Agid, Y; Chase, T; Marsden, D	1
Aquilonius, SM; Hansson, LE; Johansson, K; Nilsson, D; Nyström, C; Paalzow, L	1
Hirano, M; Imai, T; Ito, H; Kawamura, J; Matsumoto, S; Tamaru, Y; Ueno, S	1
Arias, M; Lema, C; Requena, I	1
Hägglund, J; Heinonen, EH; Kaugesaar, T; Kontants, H; Mäki-Ikola, O; Pålhagen, S; Palm, R; Turunen, J	1
Albani, F; Baruzzi, A; Contin, M; Cortelli, P; Martinelli, P; Riva, R	1
Katayama, S; Khoriyama, T; Mao, JJ; Nakamura, S; Oka, M; Tahara, E; Watanabe, C; Yamamura, Y	1
Buchholz, J; Iacono, RP; Kuniyoshi, S; Liu, H; Schoonenberg, T	1
Hauser, RA; Zesiewicz, TA	1
Stacy, M	2
Evidente, VG; Gwinn-Hardy, K; Hardy, J; Muenter, MD; Waters, C	1
Damier, P	1
Behari, M; Denny, AP	1
Kempster, PA; Reardon, KA; Shiff, M	1
Grimes, DA; Lang, AE	1
Brotchie, JM; Crossman, AR; Fox, SH; Henry, B; Peggs, D	1
Sawaishi, Y; Takada, G; Watanabe, Y; Yano, T	1
DeLong, MR; Rye, DB	1
Gottwald, MD	1
Luer, MS	1
Scheife, RT	1
Chuda, M; Hayabara, T; Ihara, Y; Kuroda, S	1
Byrne, P; Detta, A; Hitchcock, E; Kudoh, C; Meyer, C	1
Shulman, LM	1
Weiner, WJ	1
Giladi, N; Kandinov, B; Korczyn, AD; Orlov, Y; Paleacu, D; Shabtai, H; Simon, ES; Treves, TA	2
Blasucci, LM; Goetz, CG; Stebbins, GT	1
Busenbark, K; Hauser, RA; Hubble, JP; Koller, WC; Malapira, T; Olanow, CW	1
Allain, H; Bentué-Ferrer, D; Destée, A; Le Cavorzin, P; Patay, M; Petit, H; Schück, S	1
Brefel-Courbon, C	1
Quinn, N; Schrag, A	1
Fujimoto, K; Nakano, I	1
Kidd, PM	1
Onofrj, M; Paci, C; Thomas, A	1
Rajput, AH	1
Avison, MJ; Berger, JR; Maragos, WF; Nath, A; Schmitt, FA	1
Albani, F; Baruzzi, A; Contin, M; Martinelli, P; Riva, R	1
Ferrarini, M; Filippini, G; Girotti, F; Monza, D; Soliveri, P; Testa, D	1
Goetz, CG; Leurgans, S; Pappert, EJ; Raman, R; Stemer, AB	1
Albanese, A; Bentivoglio, AR; Cortelli, P; Elia, A; Ferraris, A; Ialongo, T; Montagna, P; Valente, EM	1
Badarna, S; Front, A; Giladi, N; Hardoff, R; Honigman, S; Soil, A; Sula, M; Tamir, A	1
Inoue, K; Mochio, S; Oka, H	1
Ahlskog, JE; Apaydin, H; Boeve, BF; Dickson, DW; Parisi, JE	1
Buhmann, C; Oechsner, M; Strauss, J; Stuerenburg, HJ	1
Morrish, P	1
Jellinger, K; Seppi, K; Tison, F; Wenning, GK	1
Suchowersky, O	1
Hickey, MA; Morton, AJ; Reynolds, GP	1

Reviews

88 review(s) available for levodopa and Disease Exacerbation

Article	Year
New dopaminergic therapies for PD motor complications. Neuropharmacology, 2022, 02-15, Volume: 204 Topics: Alanine; Antiparkinson Agents; Apomorphine; Benzylamines; Delayed-Action Preparations; Disease Progression; Dopamine Agents; Dopamine Agonists; Drug Compounding; Drug Delivery Systems; Dyskinesias; Humans; Levodopa; Oxadiazoles; Parkinson Disease	2022
Closing the loop for patients with Parkinson disease: where are we? Nature reviews. Neurology, 2022, Volume: 18, Issue:8 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease; Quality of Life	2022
Neuroprotective approaches to halt Parkinson's disease progression. Neurochemistry international, 2022, Volume: 158 Topics: Antiparkinson Agents; Disease Progression; Dopamine; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life	2022
How I treat Parkinson's disease. Arquivos de neuro-psiquiatria, 2022, Volume: 80, Issue:5 Suppl 1 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease; Quality of Life	2022
Considerations for developing a targeted amino acid supplement for people with Parkinson's disease that promotes health while accounting for pathophysiology and medication interference. Nutrition reviews, 2023, 07-10, Volume: 81, Issue:8 Topics: Amino Acids; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease	2023
Ambiental Factors in Parkinson's Disease Progression: A Systematic Review. Medicina (Kaunas, Lithuania), 2023, Feb-05, Volume: 59, Issue:2 Topics: Aged; Air Pollutants; Disease Progression; Female; Humans; Levodopa; Parkinson Disease; Particulate Matter	2023
Parkinson's disease - current treatment. Current opinion in neurology, 2023, 08-01, Volume: 36, Issue:4 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2023
Effective Treatment Strategies for Motor and Nonmotor Symptoms of Parkinson Disease. The Journal of clinical psychiatry, 2020, 01-07, Volume: 81, Issue:1 Topics: Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Parkinson Disease	2020
Diagnosis and Treatment of Parkinson Disease: A Review. JAMA, 2020, 02-11, Volume: 323, Issue:6 Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Levodopa; Parkinson Disease; Prognosis	2020
Challenges and Perspectives in the Management of Late-Stage Parkinson's Disease. Journal of Parkinson's disease, 2020, Volume: 10, Issue:s1 Topics: Antiparkinson Agents; Disease Management; Disease Progression; Humans; Levodopa; Palliative Care; Parkinson Disease	2020
The Effect of Caffeine on the Risk and Progression of Parkinson's Disease: A Meta-Analysis. Nutrients, 2020, Jun-22, Volume: 12, Issue:6 Topics: Caffeine; Coffee; Cohort Studies; Disease Progression; Humans; Levodopa; Parkinson Disease; Proportional Hazards Models	2020
An evaluation of subcutaneous apomorphine for the treatment of Parkinson's disease. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:14 Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Dopamine Agonists; Humans; Injection Site Reaction; Injections, Subcutaneous; Levodopa; Parkinson Disease; Subcutaneous Tissue	2020
Pathophysiology, Patient Burden, and Recognition of OFF Episodes of Parkinson Disease. The Journal of clinical psychiatry, 2020, 10-27, Volume: 81, Issue:6 Topics: Antiparkinson Agents; Cost of Illness; Disease Progression; Humans; Levodopa; Parkinson Disease; Physician-Patient Relations; Quality of Life	2020
Improving the Delivery of Levodopa in Parkinson's Disease: A Review of Approved and Emerging Therapies. CNS drugs, 2020, Volume: 34, Issue:11 Topics: Administration, Oral; Animals; Antiparkinson Agents; Disease Progression; Drug Delivery Systems; Half-Life; Humans; Levodopa; Parkinson Disease	2020
Anxiety: An ignored aspect of Parkinson's disease lacking attention. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2020, Volume: 131 Topics: Animals; Anti-Anxiety Agents; Antiparkinson Agents; Anxiety; Disease Progression; Humans; Levodopa; Parkinson Disease	2020
Pharmacotherapy in Parkinson’s disease. Medizinische Monatsschrift fur Pharmazeuten, 2016, Volume: 39, Issue:7 Topics: Antiparkinson Agents; Clinical Trials as Topic; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Guideline Adherence; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neurologic Examination; Parkinson Disease; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate	2016
Pharmacokinetics of monoamine oxidase B inhibitors in Parkinson's disease: current status. Expert opinion on drug metabolism & toxicology, 2019, Volume: 15, Issue:5 Topics: Antiparkinson Agents; Disease Progression; Dopamine; Humans; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index	2019
[What is the Best Initial Treatment for Parkinson's Disease? New Clinical Practice Guideline and My Personal Opinion]. Brain and nerve = Shinkei kenkyu no shinpo, 2019, Volume: 71, Issue:8 Topics: Disease Progression; Dopamine; Exercise; Humans; Levodopa; Parkinson Disease; Practice Guidelines as Topic; Substantia Nigra	2019
[Advanced Parkinson's disease]. Psychologie & neuropsychiatrie du vieillissement, 2006, Volume: 4 Spec No 1 Topics: Aged; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease	2006
Detoxification and antioxidative therapy for levodopa-induced neurodegeneration in Parkinson's disease. Expert review of neurotherapeutics, 2013, Volume: 13, Issue:6 Topics: Aging; Animals; Antioxidants; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Inactivation, Metabolic; Levodopa; Nerve Degeneration; Oxidative Stress; Parkinson Disease	2013
Therapeutic prospects for Parkinson disease. Annals of neurology, 2013, Volume: 74, Issue:3 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease	2013
Continuous drug delivery in Parkinson's disease. CNS drugs, 2014, Volume: 28, Issue:1 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dopamine Agents; Drug Delivery Systems; Humans; Levodopa; Parkinson Disease	2014
Safinamide for the treatment of Parkinson's disease. Expert review of clinical pharmacology, 2014, Volume: 7, Issue:6 Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Disease Progression; Dopamine; Dopamine Agents; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease	2014
Targeting glutamatergic synapses in Parkinson's disease. Current opinion in pharmacology, 2015, Volume: 20 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopaminergic Neurons; Dyskinesia, Drug-Induced; Humans; Levodopa; Molecular Targeted Therapy; Parkinson Disease; Receptors, Ionotropic Glutamate; Synaptic Transmission	2015
Presse medicale (Paris, France : 1983), 2017, Volume: 46, Issue:2 Pt 1 Topics: Antiparkinson Agents; Articulation Disorders; Corpus Striatum; Deglutition Disorders; Disease Progression; Dopamine Agonists; Dopaminergic Neurons; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Movement; Muscle Hypertonia; Parkinson Disease; Parkinsonian Disorders; Postural Balance; Sensation Disorders; Substantia Nigra; Tremor	2017
Treatment challenges in Parkinson's disease. The Nurse practitioner, 2008, Volume: 33, Issue:7 Topics: Algorithms; Antiparkinson Agents; Communication; Continuity of Patient Care; Decision Trees; Disease Progression; Dopamine Agents; Drug Monitoring; Humans; Interprofessional Relations; Levodopa; Monoamine Oxidase Inhibitors; Nurse Practitioners; Nurse's Role; Nursing Assessment; Parkinson Disease; Primary Health Care; Surveys and Questionnaires	2008
The clinical spectrum of freezing of gait in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23 Suppl 2 Topics: Disease Progression; Freezing Reaction, Cataleptic; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease	2008
Levodopa-related motor complications--phenomenology. Movement disorders : official journal of the Movement Disorder Society, 2008, Volume: 23 Suppl 3 Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Drug Administration Schedule; Dyskinesias; Fatigue; Humans; Levodopa; Mood Disorders; Motor Activity; Parkinson Disease; Treatment Failure	2008
Levodopa in the early treatment of Parkinson's disease. Parkinsonism & related disorders, 2009, Volume: 15 Suppl 1 Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors	2009
The effect of onset age on the clinical features of Parkinson's disease. European journal of neurology, 2009, Volume: 16, Issue:4 Topics: Adult; Age of Onset; Aged; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Dystonia; Humans; Levodopa; Middle Aged; Parkinson Disease; Phenotype; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome	2009
Mechanisms compensating for dopamine loss in early Parkinson disease. Neurology, 2009, Feb-17, Volume: 72, Issue:7 Suppl Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease	2009
Levodopa-related wearing-off in Parkinson's disease: identification and management. Current medical research and opinion, 2009, Volume: 25, Issue:4 Topics: Antiparkinson Agents; Cost of Illness; Disabled Persons; Disease Progression; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Dyskinesia, Drug-Induced; Health Surveys; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Surveys and Questionnaires; Time Factors	2009
Pharmacologic management of Parkinson's disease in long-term care residents: maintaining functionality to improve quality of life. Director (Cincinnati, Ohio), 2007,Spring, Volume: 15, Issue:2 Topics: Accidental Falls; Activities of Daily Living; Aged; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Disease Progression; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Humans; Levodopa; Long-Term Care; Monoamine Oxidase Inhibitors; Nursing Homes; Parkinson Disease; Patient Care Planning; Practice Guidelines as Topic; Quality of Life; Safety Management	2007
Early pharmacologic treatment in Parkinson's disease. The American journal of managed care, 2010, Volume: 16 Suppl Implications Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Ubiquinone; Vitamin E	2010
Deep brain stimulation state of the art and novel stimulation targets. Progress in brain research, 2010, Volume: 184 Topics: Animals; Antiparkinson Agents; Contraindications; Deep Brain Stimulation; Disease Progression; Humans; Levodopa; Parkinson Disease; Quality of Life; Treatment Outcome	2010
Motor complications, levodopa metabolism and progression of Parkinson's disease. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Animals; Arteriosclerosis; Catechol O-Methyltransferase; Disease Progression; Dopamine; Dyskinesias; Enzyme Inhibitors; Free Radicals; Homocysteine; Humans; Levodopa; Nerve Degeneration; Parkinson Disease; Synaptic Transmission	2011
Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?". The neurologist, 2011, Volume: 17, Issue:6 Suppl 1 Topics: Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Dyskinesia, Drug-Induced; Goals; Humans; Levodopa; Parkinson Disease; Patient Compliance	2011
Neuroprotective role of dopamine agonists: evidence from animal models and clinical studies. The neurologist, 2011, Volume: 17, Issue:6 Suppl 1 Topics: Animals; Antiparkinson Agents; Clinical Trials as Topic; Disease Models, Animal; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease	2011
Advanced strategies for treatment of Parkinson's disease: the role of early treatment. The American journal of managed care, 2011, Volume: 17 Suppl 12 Topics: Antiparkinson Agents; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Early Diagnosis; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality-Adjusted Life Years; Secondary Prevention	2011
Implications for managed care for improving outcomes in Parkinson's disease: balancing aggressive treatment with appropriate care. The American journal of managed care, 2011, Volume: 17 Suppl 12 Topics: Antiparkinson Agents; Costs and Cost Analysis; Disease Progression; Dose-Response Relationship, Drug; Exercise; Humans; Levodopa; Managed Care Programs; Parkinson Disease; Patient-Centered Care; Physical Therapy Modalities; Quality of Life; Sickness Impact Profile	2011
Updates in the medical management of Parkinson disease. Cleveland Clinic journal of medicine, 2012, Volume: 79, Issue:1 Topics: Age Factors; Amantadine; Antiparkinson Agents; Apomorphine; Catechol O-Methyltransferase; Cholinergic Antagonists; Disease Progression; Dopamine Agents; Humans; Levodopa; Monoamine Oxidase; Parkinson Disease	2012
Functional neuroimaging in Parkinson's disease. Cold Spring Harbor perspectives in medicine, 2012, Volume: 2, Issue:5 Topics: Antiparkinson Agents; Brain Diseases, Metabolic; Cognition Disorders; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Fluorodeoxyglucose F18; Functional Neuroimaging; Humans; Levodopa; Lewy Bodies; Magnetic Resonance Imaging; Neurotransmitter Agents; Parkinson Disease; Positron-Emission Tomography; Psychomotor Disorders; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon	2012
Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists. Journal of neurology, 2002, Volume: 249 Suppl 2 Topics: Animals; Antiparkinson Agents; Bromocriptine; Contraindications; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Receptors, Dopamine	2002
Parkinson's disease: current scientific understanding, and John's story. Journal of psychosocial nursing and mental health services, 2002, Volume: 40, Issue:10 Topics: Antiparkinson Agents; Disease Progression; Drug Monitoring; Drug Therapy, Combination; History, 19th Century; History, 20th Century; Humans; Levodopa; Male; Parkinson Disease	2002
Differential diagnosis between early Parkinson's disease and dementia with Lewy bodies. Advances in neurology, 2003, Volume: 91 Topics: Brain; Cognition Disorders; Diagnosis, Differential; Disease Progression; Hallucinations; Humans; Levodopa; Lewy Body Disease; Mood Disorders; Parkinson Disease	2003
Do dopamine agonists or levodopa modify Parkinson's disease progression? European journal of neurology, 2002, Volume: 9 Suppl 3 Topics: Animals; Antiparkinson Agents; Benzothiazoles; Carrier Proteins; Dihydroxyphenylalanine; Disease Progression; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Humans; Indoles; Iodine Radioisotopes; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Tropanes	2002
Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. Journal of neural transmission. Supplementum, 2003, Issue:65 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine; Selegiline	2003
[Therapy for patients with progressive Parkinson's disease]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8 Topics: Antiparkinson Agents; Disease Progression; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Life Style; Parkinson Disease	2003
Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology, 2003, Sep-23, Volume: 61, Issue:6 Suppl 3 Topics: Antiparkinson Agents; Biomarkers; Clinical Trials as Topic; Diagnostic Imaging; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Radionuclide Imaging; Treatment Outcome	2003
Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Experimental neurology, 2003, Volume: 184 Suppl 1 Topics: Animals; Basal Ganglia; Biomarkers; Cocaine; Diagnostic Imaging; Dihydroxyphenylalanine; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Parkinson Disease; Radiopharmaceuticals; Technology Assessment, Biomedical; Tetrabenazine; Tomography, Emission-Computed, Single-Photon; Vesicular Biogenic Amine Transport Proteins; Vesicular Monoamine Transport Proteins	2003
[Progressive subcortical gliosis]. Ryoikibetsu shokogun shirizu, 2003, Issue:40 Topics: Antipsychotic Agents; Cerebral Cortex; Diagnosis, Differential; Disease Progression; Gliosis; Humans; Levodopa; Mental Disorders	2003
Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Experimental neurology, 2003, Volume: 184, Issue:1 Topics: Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesias; Dystonia; Humans; Levodopa; Long-Term Care; Parkinson Disease	2003
Unmet medical needs in Parkinson's disease. Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1 Topics: Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease	2004
The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology, 2004, Jan-13, Volume: 62, Issue:1 Suppl 1 Topics: Animals; Antiparkinson Agents; Basal Ganglia; Disease Progression; Dopamine; Humans; Levodopa; Nerve Net; Neurons; Parkinson Disease	2004
Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology, 2004, Sep-14, Volume: 63, Issue:5 Topics: Antiparkinson Agents; Arteriosclerosis; Catechol O-Methyltransferase; Dementia; Disease Progression; Disease Susceptibility; Homocysteine; Humans; Hyperhomocysteinemia; Inflammation; Levodopa; Models, Biological; Multicenter Studies as Topic; Oxidative Stress; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra	2004
Treatment challenges in early stage Parkinson's disease. Neurologic clinics, 2004, Volume: 22, Issue:3 Suppl Topics: Aged; Antiparkinson Agents; Disease Progression; Early Diagnosis; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Neuroprotective Agents; Parkinson Disease	2004
ALS lessons learned from other neurological diseases. Parkinson's disease. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 2004, Volume: 5 Suppl 1 Topics: Amyotrophic Lateral Sclerosis; Antiparkinson Agents; Behavioral Symptoms; Coenzymes; Controlled Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Ubiquinone	2004
A walk through the management of Parkinson s disease. Annals of the Academy of Medicine, Singapore, 2005, Volume: 34, Issue:2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Deep Brain Stimulation; Disease Progression; Dopamine; Dopamine Agonists; Dyskinesias; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Receptors, Dopamine	2005
Does levodopa slow or hasten the rate of progression of Parkinson's disease? Journal of neurology, 2005, Volume: 252 Suppl 4 Topics: Antiparkinson Agents; Brain; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Levodopa; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome	2005
Present and future drug treatment for Parkinson's disease. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:11 Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence	2005
Patient page. Slowing down a "slow" movement disorder: selegiline's benefit in treating Parkinson disease. Neurology, 2006, Apr-25, Volume: 66, Issue:8 Topics: Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease; Selegiline	2006
Levodopa, motor fluctuations and dyskinesia in Parkinson's disease. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:13 Topics: Animals; Disease Progression; Dyskinesias; Humans; Levodopa; Motor Neuron Disease; Parkinson Disease; Risk Factors	2006
Medical management of advanced Parkinson's disease. Clinics in geriatric medicine, 2006, Volume: 22, Issue:4 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Neurosurgical Procedures; Parkinson Disease; Treatment Outcome	2006
Locomotor training in people with Parkinson disease. Physical therapy, 2006, Volume: 86, Issue:10 Topics: Antiparkinson Agents; Disease Management; Disease Progression; Humans; Levodopa; Locomotion; Parkinson Disease; Physical Therapy Modalities	2006
Parkinson disease: managing a complex, progressive disease at all stages. Cleveland Clinic journal of medicine, 2007, Volume: 74, Issue:5 Topics: Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Gait; Humans; Levodopa; Parkinson Disease	2007
Managing patients with Parkinson's disease. The Practitioner, 2007, Volume: 251, Issue:1694 Topics: Antiparkinson Agents; Depressive Disorder; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Patient Care Planning; Selective Serotonin Reuptake Inhibitors	2007
[Lewy body dementia and Parkinson disease dementia]. Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:10 Pt 2 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Dementia; Diagnosis, Differential; Disease Progression; Dopamine Agents; Humans; Iatrogenic Disease; Levodopa; Lewy Body Disease; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Parkinsonian Disorders; Phenylcarbamates; Psychotropic Drugs; Rivastigmine; Serotonin Antagonists	2007
Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS drugs, 2007, Volume: 21, Issue:8 Topics: Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease	2007
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor]. MMW Fortschritte der Medizin, 2007, May-21, Volume: 149 Suppl 2 Topics: Adrenergic beta-Antagonists; Amantadine; Anticonvulsants; Antiparkinson Agents; Deep Brain Stimulation; Diagnosis, Differential; Disease Progression; Drug Therapy, Combination; Electroencephalography; Humans; Levodopa; Middle Aged; Parkinson Disease; Practice Guidelines as Topic; Primidone; Tremor	2007
The relationship of Parkinson disease with aging. Archives of neurology, 2007, Volume: 64, Issue:9 Topics: Aging; Antiparkinson Agents; Cognition Disorders; Dementia; Disease Progression; Gait; Humans; Levodopa; Parkinson Disease; Posture	2007
Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Current medicinal chemistry, 2007, Volume: 14, Issue:22 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Humans; Levodopa; Locus Coeruleus; Neurons; Norepinephrine; Parkinson Disease; Receptors, Adrenergic; Receptors, Dopamine	2007
The neural mechanisms and progressive nature of symptoms of Parkinson's disease--based on clinical, neurophysiological and morphological studies. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 10, Issue:1 Topics: Dihydroxyphenylalanine; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Movement Disorders; Nervous System; Parkinson Disease	1995
Pharmacokinetic optimisation in the treatment of Parkinson's disease. Clinical pharmacokinetics, 1996, Volume: 30, Issue:6 Topics: Antiparkinson Agents; Delayed-Action Preparations; Disease Progression; Dopamine Agonists; Humans; Levodopa; Muscarinic Antagonists; Parkinson Disease	1996
[Clinical characteristics and trends in research of Parkinson's disease and parkinsonism in Japan]. Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Child; Child, Preschool; Disease Progression; Dopamine Agonists; Female; Humans; Infant; Japan; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease	1997
[Clinical classifications of Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:1 Topics: Age of Onset; Antiparkinson Agents; Disease Progression; Drug Tolerance; Humans; Levodopa; Parkinson Disease	1997
[Brain tumor and parkinsonism]. Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55, Issue:1 Topics: Antiparkinson Agents; Brain Neoplasms; Disease Progression; Humans; Levodopa; Parkinson Disease	1997
Problems with current pharmacologic treatment of Parkinson's disease. Experimental neurology, 1997, Volume: 144, Issue:1 Topics: Antiparkinson Agents; Cognition Disorders; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease; Posture	1997
Pharmacodynamic and pharmacokinetic features of cabergoline. Rationale for use in Parkinson's disease. Drugs, 1998, Volume: 55 Suppl 1 Topics: Animals; Antiparkinson Agents; Area Under Curve; Cabergoline; Disease Progression; Dopamine Agonists; Ergolines; Female; Humans; Levodopa; Male; Parkinson Disease; Rats; Receptors, Dopamine D1; Receptors, Dopamine D2	1998
Management of early Parkinson's disease. The Medical clinics of North America, 1999, Volume: 83, Issue:2 Topics: Animals; Antiparkinson Agents; Disease Progression; Dopamine Agents; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Selegiline; Treatment Outcome	1999
Managing late complications of Parkinson's disease. The Medical clinics of North America, 1999, Volume: 83, Issue:2 Topics: Cognition Disorders; Disease Progression; Dopamine Agents; Gait; Humans; Levodopa; Parkinson Disease; Treatment Outcome	1999
Evidence suggesting the role of norepinephrine deficiency in late stages of Parkinson's disease. Advances in neurology, 1999, Volume: 80 Topics: Antiparkinson Agents; Disease Progression; Dopamine beta-Hydroxylase; Droxidopa; Globus Pallidus; Humans; Levodopa; Norepinephrine; Parkinson Disease; Thalamus	1999
New aspects in the pathophysiology of dyskinesia. Salpêtrière Deep Brain Stimulation Group. Advances in neurology, 1999, Volume: 80 Topics: Animals; Antiparkinson Agents; Brain; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation; Humans; Levodopa; Neurology; Parkinson Disease	1999
Treatment of early Parkinson's disease. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1999, Volume: 26 Suppl 2 Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Time Factors	1999
Interventions to achieve tonic exposure to levodopa: delaying or preventing the onset of motor complications. Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Nitriles; Parkinson Disease	1999
[ What drug strategies are advisable for patients with advanced-stage Parkinson's]. Revue neurologique, 2000, Volume: 156 Suppl 2 Pt 2 Topics: Age Factors; Aged; Antiparkinson Agents; Disease Progression; Drug Therapy, Combination; Humans; Levodopa; Parkinson Disease	2000
[Rating scale and functional prognosis of Parkinson's disease]. Nihon rinsho. Japanese journal of clinical medicine, 2000, Volume: 58, Issue:10 Topics: Disability Evaluation; Disease Progression; Humans; Levodopa; Movement; Parkinson Disease; Prognosis; Severity of Illness Index; Stereotaxic Techniques	2000
Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Alternative medicine review : a journal of clinical therapeutic, 2000, Volume: 5, Issue:6 Topics: Disease Progression; Electron Transport; Humans; Levodopa; Mitochondria; Neurodegenerative Diseases; Oxidation-Reduction; Parkinson Disease, Secondary; Parkinsonian Disorders	2000
Parkinson's disease: medical treatment of moderate to advanced disease. Current neurology and neuroscience reports, 2002, Volume: 2, Issue:4 Topics: Amantadine; Anti-Anxiety Agents; Antidepressive Agents; Antiparkinson Agents; Antipsychotic Agents; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Cholinergic Antagonists; Cognition Disorders; Disease Progression; Dopamine Agonists; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease	2002

Trials

52 trial(s) available for levodopa and Disease Exacerbation

Article	Year
Trial of Deferiprone in Parkinson's Disease. The New England journal of medicine, 2022, 12-01, Volume: 387, Issue:22 Topics: Administration, Oral; Antiparkinson Agents; Brain; Brain Chemistry; Deferiprone; Disease Progression; Dopamine Agents; Double-Blind Method; Humans; Iron; Iron Chelating Agents; Levodopa; Neutropenia; Parkinson Disease; Substantia Nigra	2022
Two-Year Agility Maintenance Training Slows the Progression of Parkinsonian Symptoms. Medicine and science in sports and exercise, 2019, Volume: 51, Issue:2 Topics: Aged; Antiparkinson Agents; Disease Progression; Exercise Therapy; Humans; Levodopa; Middle Aged; Parkinson Disease; Postural Balance; Quality of Life; Treatment Outcome	2019
Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. The New England journal of medicine, 2019, 01-24, Volume: 380, Issue:4 Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Time-to-Treatment	2019
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial. The international journal of neuropsychopharmacology, 2013, Volume: 16, Issue:7 Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease	2013
Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study. BMC neurology, 2015, Nov-19, Volume: 15 Topics: Antiparkinson Agents; Carbidopa; Cost-Benefit Analysis; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Humans; Levodopa; Netherlands; Parkinson Disease; Quality of Life; Time-to-Treatment	2015
Fluctuating functions related to quality of life in advanced Parkinson disease: effects of duodenal levodopa infusion. Acta neurologica Scandinavica, 2008, Volume: 118, Issue:6 Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Depressive Disorder; Disease Progression; Duodenum; Female; Gait Disorders, Neurologic; Humans; Hyperkinesis; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Movement Disorders; Parkinson Disease; Patient Satisfaction; Quality of Life; Sickness Impact Profile; Surveys and Questionnaires; Treatment Outcome	2008
Deep brain stimulation for Parkinson's disease. The Medical letter on drugs and therapeutics, 2009, Apr-06, Volume: 51, Issue:1309 Topics: Aged; Antiparkinson Agents; Deep Brain Stimulation; Disease Progression; Female; Humans; Levodopa; Male; Neurosurgical Procedures; Parkinson Disease	2009
Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Archives of neurology, 2009, Volume: 66, Issue:5 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Cohort Studies; Disability Evaluation; Disease Progression; Early Diagnosis; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Outcome Assessment, Health Care; Parkinson Disease; Pramipexole; Quality of Life; Time; Treatment Outcome	2009
Depressive symptoms impacting on health-related quality of life in early Parkinson's disease: results from Chinese L-dopa exposed cohort. Clinical neurology and neurosurgery, 2009, Volume: 111, Issue:9 Topics: Aged; Antiparkinson Agents; China; Cohort Studies; Depressive Disorder; Disease Progression; Double-Blind Method; Female; Ganoderma; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phytotherapy; Quality of Life; Regression Analysis; Surveys and Questionnaires; Treatment Outcome	2009
Long-term efficacy of rasagiline in early Parkinson's disease. The International journal of neuroscience, 2010, Volume: 120, Issue:6 Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome	2010
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Annals of neurology, 2010, Volume: 68, Issue:1 Topics: Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopamine Agents; Double-Blind Method; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Enzyme Inhibitors; Female; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Risk; Time Factors; Treatment Outcome	2010
Characteristics of the sequence effect in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2010, Oct-15, Volume: 25, Issue:13 Topics: Aged; Antiparkinson Agents; Cross-Over Studies; Disability Evaluation; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Severity of Illness Index; Transcranial Magnetic Stimulation	2010
Improvements in both psychosis and motor signs in Parkinson's disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Aug-15, Volume: 35, Issue:7 Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Clinical Trials, Phase I as Topic; Dibenzothiazepines; Disease Progression; Electroconvulsive Therapy; Electroencephalography; Female; Humans; Inpatients; Levodopa; Male; Middle Aged; Parkinson Disease; Psychotic Disorders; Quetiapine Fumarate; Regional Blood Flow; Risk Factors; Time Factors; Tokyo; Tomography, Emission-Computed, Single-Photon	2011
Effectiveness of intensive inpatient rehabilitation treatment on disease progression in parkinsonian patients: a randomized controlled trial with 1-year follow-up. Neurorehabilitation and neural repair, 2012, Volume: 26, Issue:2 Topics: Acoustic Stimulation; Activities of Daily Living; Aged; Antiparkinson Agents; Critical Care; Cues; Disease Progression; Exercise Test; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Photic Stimulation; Physical Therapy Modalities; Pilot Projects; Statistics, Nonparametric; Treatment Outcome	2012
A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:12 Topics: Aged; Antiparkinson Agents; Dihydroxyphenylalanine; Disease Progression; Fluorine Radioisotopes; Follow-Up Studies; Humans; Indoles; Levodopa; Middle Aged; Parkinson Disease; Tomography, Emission-Computed	2002
[Pergolide: a useful agonist for the treatment of Parkinson disease]. Revue neurologique, 2002, Volume: 158, Issue:6-7 Topics: Antiparkinson Agents; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pergolide	2002
Executive function differences in multiple system atrophy and Parkinson's disease. Parkinsonism & related disorders, 2003, Volume: 9, Issue:4 Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Color Perception; Disease Progression; Female; Humans; Levodopa; Male; Memory; Middle Aged; Multiple System Atrophy; Neuropsychological Tests; Parkinson Disease; Psychomotor Performance; Verbal Behavior	2003
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of neurology, 2003, Volume: 54, Issue:1 Topics: Adult; Aged; Brain; Caudate Nucleus; Corpus Striatum; Disease Progression; Dopamine; Dopamine Agonists; Double-Blind Method; Female; Fluorine Radioisotopes; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Putamen; Receptors, Dopamine D2; Severity of Illness Index; Substantia Nigra; Tomography, Emission-Computed	2003
Do patients with Parkinson's disease benefit from embryonic dopamine cell transplantation? Journal of neurology, 2003, Volume: 250 Suppl 3 Topics: Brain; Brain Tissue Transplantation; Disease Progression; Dopamine; Double-Blind Method; Embryo, Mammalian; Fetal Tissue Transplantation; Humans; Levodopa; Middle Aged; Neurons; Parkinson Disease; Stem Cell Transplantation; Tomography, Emission-Computed; Transplants; Treatment Outcome	2003
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. Journal of neural transmission (Vienna, Austria : 1996), 2004, Volume: 111, Issue:8 Topics: Aged; Antiparkinson Agents; Apoptosis; Caspase 3; Caspases; Cell Survival; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Lymphocytes; Male; Middle Aged; Parkinson Disease; Peripheral Nervous System; Proto-Oncogene Proteins c-bcl-2; Receptors, GABA-A; Superoxide Dismutase	2004
Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourology and urodynamics, 2004, Volume: 23, Issue:7 Topics: Adult; Antiparkinson Agents; Disease Progression; Dopamine Agents; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Sex Characteristics; Surveys and Questionnaires; Urinary Bladder Diseases; Urination Disorders; Urodynamics; Urologic Diseases	2004
Long-term follow-up study with repetitive transcranial magnetic stimulation (rTMS) in Parkinson's disease. Brain research bulletin, 2004, Sep-30, Volume: 64, Issue:3 Topics: Aged; Antiparkinson Agents; Brain; Disease Progression; Dose-Response Relationship, Drug; Electric Stimulation Therapy; Follow-Up Studies; Humans; Levodopa; Middle Aged; Neural Pathways; Parkinson Disease; Retrospective Studies; Time Factors; Transcranial Magnetic Stimulation; Treatment Outcome	2004
Levodopa and the progression of Parkinson's disease. The New England journal of medicine, 2004, Dec-09, Volume: 351, Issue:24 Topics: Aged; Antiparkinson Agents; Carbidopa; Corpus Striatum; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Double-Blind Method; Drug Combinations; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Parkinson Disease; Tomography, Emission-Computed, Single-Photon	2004
Levodopa and the progression of Parkinson's disease. Current neurology and neuroscience reports, 2005, Volume: 5, Issue:4 Topics: Aged; Cocaine; Corpus Striatum; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Oxidative Stress; Parkinson Disease; Presynaptic Terminals; Substantia Nigra; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2005
Selegiline slows the progression of the symptoms of Parkinson disease. Neurology, 2006, Apr-25, Volume: 66, Issue:8 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Selegiline; Time Factors	2006
Levodopa availability improves with progression of Parkinson's disease. Journal of neurology, 2006, Volume: 253, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Area Under Curve; Chromatography, High Pressure Liquid; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics as Topic; Time Factors	2006
Levodopa induced motor complications in Thai Parkinson's disease patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2006, Volume: 89, Issue:5 Topics: Aged; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Female; Humans; Hypokinesia; Levodopa; Male; Parkinson Disease; Thailand	2006
Longitudinal study of the motor response to levodopa in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Motor Skills; Neurologic Examination; Parkinson Disease	2006
Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharmaceutical research, 2007, Volume: 24, Issue:4 Topics: Antiparkinson Agents; Cohort Studies; Computer Simulation; Disease Progression; Follow-Up Studies; Humans; Levodopa; Models, Biological; Parkinson Disease; Predictive Value of Tests; Reproducibility of Results; Research Design; Time Factors; Treatment Outcome	2007
Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement disorders : official journal of the Movement Disorder Society, 2007, Volume: 22, Issue:16 Topics: Aged; Amantadine; Antiparkinson Agents; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Treatment Outcome	2007
Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. Journal of neural transmission. Parkinson's disease and dementia section, 1995, Volume: 9, Issue:2-3 Topics: Adult; Aged; Aging; Antiparkinson Agents; Bromocriptine; Disease Progression; Female; Gait; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Psychomotor Performance; Tremor	1995
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group. Annals of neurology, 1996, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Antiparkinson Agents; Disabled Persons; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease, Secondary; Selegiline; Treatment Outcome; Vitamin E	1996
Parkinson's disease: progression and mortality in the L-DOPA era. Advances in neurology, 1996, Volume: 69 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cause of Death; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Hypotension, Orthostatic; Levodopa; Life Expectancy; Male; Middle Aged; Parkinson Disease; Survival Analysis	1996
Progression and prognosis in Parkinson's disease in relation to concomitant cerebral or peripheral vasculopathy. Advances in neurology, 1996, Volume: 69 Topics: Aged; Antiparkinson Agents; Blood Vessels; Cerebrovascular Circulation; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Multivariate Analysis; Parkinson Disease; Prognosis; Regional Blood Flow; Survival Analysis	1996
Striatal dopamine D2 receptor alterations and response to L-DOPA in Parkinson's disease. A [123I]IBZM SPET study. Advances in neurology, 1996, Volume: 69 Topics: Adult; Age of Onset; Aged; Aging; Antiparkinson Agents; Disease Progression; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Neostriatum; Parkinson Disease; Receptors, Dopamine D2; Tomography, Emission-Computed, Single-Photon	1996
Effects of L-DOPA on spatiotemporal contrast sensitivity in Parkinson's disease. Advances in neurology, 1996, Volume: 69 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Contrast Sensitivity; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Space Perception; Time Perception	1996
A study on the effect and tolerance of lisuride on Parkinson's disease. Advances in neurology, 1996, Volume: 69 Topics: Age of Onset; Aged; Antiparkinson Agents; Benserazide; Disease Progression; Drug Therapy, Combination; Female; Humans; Levodopa; Lisuride; Male; Middle Aged; Parkinson Disease; Prolactin; Psychiatric Status Rating Scales	1996
Does thalamotomy alter the course of Parkinson's disease? Advances in neurology, 1996, Volume: 69 Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Functional Laterality; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Thalamus; Treatment Outcome; Tremor	1996
Bromocriptine therapy in early-stage Parkinson's disease. European neurology, 1996, Volume: 36, Issue:3 Topics: Antiparkinson Agents; Bromocriptine; Disease Progression; Drug Therapy, Combination; Evaluation Studies as Topic; Follow-Up Studies; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease; Time Factors; Treatment Outcome	1996
Eight-year follow-up study of bromocriptine monotherapy for Parkinson's disease. European neurology, 1996, Volume: 36 Suppl 1 Topics: Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Follow-Up Studies; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease	1996
Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Movement disorders : official journal of the Movement Disorder Society, 1997, Volume: 12, Issue:4 Topics: Aged; Antipsychotic Agents; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Parkinson Disease; Psychoses, Substance-Induced; Risperidone; Severity of Illness Index; Time Factors	1997
123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Apomorphine; Basal Ganglia Diseases; Benzamides; Chi-Square Distribution; Disease Progression; Dopamine Agonists; Follow-Up Studies; Humans; Iodine Radioisotopes; Levodopa; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	1998
Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Movement disorders : official journal of the Movement Disorder Society, 1998, Volume: 13, Issue:1 Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Confidence Intervals; Disease Progression; Dopamine Agonists; Double-Blind Method; Female; Humans; Indoles; Levodopa; Longitudinal Studies; Male; Middle Aged; Odds Ratio; Parkinson Disease; Regression Analysis; Severity of Illness Index; Treatment Outcome	1998
Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta neurologica Scandinavica, 1998, Volume: 97, Issue:3 Topics: Activities of Daily Living; Administration, Oral; Aged; Analysis of Variance; Antiparkinson Agents; Carbidopa; Disease Progression; Duodenum; Female; Humans; Infusion Pumps; Infusions, Parenteral; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Time and Motion Studies; Time Factors; Treatment Outcome; Videotape Recording	1998
Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology, 1998, Volume: 51, Issue:2 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disabled Persons; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Probability; Selegiline; Time Factors	1998
A levodopa kinetic-dynamic study of the rate of progression in Parkinson's disease. Neurology, 1998, Volume: 51, Issue:4 Topics: Adult; Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Kinetics; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prospective Studies	1998
Motor fluctuations in Parkinson's disease. Journal of the neurological sciences, 1999, May-01, Volume: 165, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dystonia; Female; Humans; Levodopa; Male; Middle Aged; Movement; Movement Disorders; Parkinson Disease; Risk Factors	1999
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3 Topics: Aged; Antiparkinson Agents; Bromocriptine; Carbidopa; Disability Evaluation; Disease Progression; Double-Blind Method; Female; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Selegiline; Substance Withdrawal Syndrome	2000
Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson's disease. The French Lisuride Study Group. European neurology, 2000, Volume: 44, Issue:1 Topics: Adult; Aged; Antiparkinson Agents; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Levodopa; Lisuride; Male; Middle Aged; Neurologic Examination; Parkinson Disease	2000
Amantadine for dyskinesia in patients affected by severe Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:1 Topics: Aged; Amantadine; Antiviral Agents; Disease Progression; Dopamine Agents; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Recovery of Function; Substance Withdrawal Syndrome; Treatment Outcome	2001
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA, 2002, Apr-03, Volume: 287, Issue:13 Topics: Aged; Antiparkinson Agents; Benzothiazoles; Brain; Cocaine; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Iodine Radioisotopes; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Degeneration; Nerve Tissue Proteins; Parkinson Disease; Pramipexole; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Regression Analysis; Thiazoles; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2002

Other Studies

218 other study(ies) available for levodopa and Disease Exacerbation

Article	Year
The cross-hemispheric nigrostriatal pathway prevents the expression of levodopa-induced dyskinesias. Neurobiology of disease, 2021, Volume: 159 Topics: Animals; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Substantia Nigra; Sympatholytics	2021
Disruption of mitochondrial complex I induces progressive parkinsonism. Nature, 2021, Volume: 599, Issue:7886 Topics: Animals; Axons; Cell Death; Dendrites; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; Electron Transport Complex I; Female; Levodopa; Male; Mice; Motor Skills; NADH Dehydrogenase; Parkinsonian Disorders; Phenotype; Substantia Nigra	2021
Profiling the most elderly parkinson's disease patients: Does age or disease duration matter? PloS one, 2021, Volume: 16, Issue:12 Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Case-Control Studies; Clinical Protocols; Comorbidity; Disease Progression; Geriatrics; Humans; Levodopa; Middle Aged; Parkinson Disease; Patient Acuity; Thailand	2021
Non-reference genome transposable elements (TEs) have a significant impact on the progression of the Parkinson's disease. Experimental biology and medicine (Maywood, N.J.), 2022, Volume: 247, Issue:18 Topics: Cross-Sectional Studies; Disease Progression; DNA Transposable Elements; Genome-Wide Association Study; Humans; Levodopa; Longitudinal Studies; Parkinson Disease; Polymorphism, Single Nucleotide; Retroelements	2022
Oculometric measures as a tool for assessment of clinical symptoms and severity of Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2023, Volume: 130, Issue:10 Topics: Aged; Disease Progression; Female; Humans; Levodopa; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Severity of Illness Index	2023
Cytosolic non-vesicular dopamine accumulation as the predominant mechanism for developing non-DOPA responsive parkinsonism in late-stage Huntington disease. Medical hypotheses, 2019, Volume: 132 Topics: Animals; Calcium; Corpus Striatum; Disease Progression; Dopamine; Humans; Huntington Disease; Levodopa; Mitochondria; Movement; Movement Disorders; Neurotransmitter Agents; Parkinsonian Disorders	2019
Levodopa response in later stages of Parkinson's disease: A case-control study. Parkinsonism & related disorders, 2020, Volume: 77 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Dementia; Disease Progression; Female; Humans; Levodopa; Male; Parkinson Disease	2020
[Current Status and Future Prospects of Therapeutic Development of Parkinson's Disease]. Brain and nerve = Shinkei kenkyu no shinpo, 2020, Volume: 72, Issue:1 Topics: alpha-Synuclein; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2020
Mathematical modeling and parameter estimation of levodopa motor response in patients with parkinson disease. PloS one, 2020, Volume: 15, Issue:3 Topics: Aged; Antiparkinson Agents; Basal Ganglia; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Models, Neurological; Motor Activity; Parkinson Disease; Time Factors; Treatment Outcome	2020
Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort. Journal of Parkinson's disease, 2020, Volume: 10, Issue:2 Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Female; Humans; Kazakhstan; Levodopa; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Sex Factors; Young Adult	2020
Initial motor reserve and long-term prognosis in Parkinson's disease. Neurobiology of aging, 2020, Volume: 92 Topics: Aged; Corpus Striatum; Disease Progression; Dopamine; Dyskinesias; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Prognosis; Time Factors	2020
Natural history of motor symptoms in Parkinson's disease and the long-duration response to levodopa. Brain : a journal of neurology, 2020, 08-01, Volume: 143, Issue:8 Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Motor Disorders; Parkinson Disease	2020
Nonlinear pharmacodynamics of levodopa through Parkinson's disease progression. Chaos (Woodbury, N.Y.), 2020, Volume: 30, Issue:9 Topics: Antiparkinson Agents; Basal Ganglia; Disease Progression; Humans; Levodopa; Parkinson Disease	2020
An integrative model of Parkinson's disease treatment including levodopa pharmacokinetics, dopamine kinetics, basal ganglia neurotransmission and motor action throughout disease progression. Journal of pharmacokinetics and pharmacodynamics, 2021, Volume: 48, Issue:1 Topics: Basal Ganglia; Computer Simulation; Disease Progression; Dopamine; Humans; Levodopa; Models, Neurological; Motor Activity; Parkinson Disease; Synaptic Transmission	2021
Parkinson Disease. American family physician, 2020, 12-01, Volume: 102, Issue:11 Topics: Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Drug Combinations; Family Practice; Humans; Levodopa; Parkinson Disease; Physical Therapy Modalities	2020
Predicting the longitudinal changes of levodopa dose requirements in Parkinson's disease using item response theory assessment of real-world Unified Parkinson's Disease Rating Scale. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:6 Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Models, Biological; Parkinson Disease; Retrospective Studies; Severity of Illness Index	2021
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson's Disease. Journal of Parkinson's disease, 2021, Volume: 11, Issue:4 Topics: Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Humans; Levodopa; Parkinson Disease	2021
The Risk Factors for the Wearing-off Phenomenon in Parkinson's Disease in Japan: A Cross-sectional, Multicenter Study. Internal medicine (Tokyo, Japan), 2017, Volume: 56, Issue:15 Topics: Age of Onset; Aged; Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Cross-Sectional Studies; Disease Progression; Female; Humans; Japan; Levodopa; Male; Middle Aged; Parkinson Disease; Quality of Life; Risk Factors; Sex Factors	2017
Effects of chronic fructose overload on renal dopaminergic system: alteration of urinary L-dopa/dopamine index correlates to hypertension and precedes kidney structural damage. The Journal of nutritional biochemistry, 2018, Volume: 51 Topics: Albuminuria; Algorithms; Animals; Biomarkers; Diet, Carbohydrate Loading; Disease Progression; Dopamine; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Fructose; Hypertension; Insulin Resistance; Kidney; Levodopa; Male; Membrane Proteins; Random Allocation; Rats, Sprague-Dawley; Receptors, Dopamine D1; Renal Elimination; Renal Insufficiency; Sodium-Potassium-Exchanging ATPase	2018
Hoehn and Yahr staging of Parkinson's disease in relation to neuropsychological measures. Frontiers in bioscience (Landmark edition), 2018, 03-01, Volume: 23, Issue:7 Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition; Disease Progression; Educational Status; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease	2018
Cardiac Sympathetic Denervation Can Predict the Wearing-off Phenomenon in Patients with Parkinson Disease. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:11 Topics: 3-Iodobenzylguanidine; Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Radionuclide Imaging; Radiopharmaceuticals; Sympathetic Nervous System	2018
Step length predicts executive dysfunction in Parkinson's disease: a 3-year prospective study. Journal of neurology, 2018, Volume: 265, Issue:10 Topics: Aged; Antiparkinson Agents; Biomechanical Phenomena; Cognitive Dysfunction; Disease Progression; Executive Function; Female; Follow-Up Studies; Gait; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prognosis; Prospective Studies	2018
Inferring the long duration response to levodopa in Parkinson's disease. Parkinsonism & related disorders, 2019, Volume: 60 Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index; Time Factors	2019
Developing and validating Parkinson's disease subtypes and their motor and cognitive progression. Journal of neurology, neurosurgery, and psychiatry, 2018, Volume: 89, Issue:12 Topics: Aged; Disease Progression; Female; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Severity of Illness Index	2018
[Devotion to painting in a Parkinson's disease patient]. Rinsho shinkeigaku = Clinical neurology, 2018, Dec-21, Volume: 58, Issue:12 Topics: Aged; Disease Progression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Humans; Levodopa; Male; Paintings; Parkinson Disease; Substance-Related Disorders	2018
The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications. Journal of the neurological sciences, 2019, 01-15, Volume: 396 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Female; Functional Laterality; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Parkinson Disease, Secondary; Severity of Illness Index	2019
[Neurology]. Revue medicale suisse, 2019, Jan-09, Volume: 15, Issue:N° 632-633 Topics: Antiparkinson Agents; Disease Progression; Drug Combinations; Humans; Levodopa; Neurology; Parkinson Disease	2019
Time dependent degeneration of the nigrostriatal tract in mice with 6-OHDA lesioned medial forebrain bundle and the effect of activin A on L-Dopa induced dyskinesia. BMC neuroscience, 2019, Feb-13, Volume: 20, Issue:1 Topics: Activins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Levodopa; Male; Medial Forebrain Bundle; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Random Allocation; Treatment Failure	2019
Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD. Neurology, 2019, 03-26, Volume: 92, Issue:13 Topics: Aged; Antiparkinson Agents; Cognitive Dysfunction; Cohort Studies; Dementia; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Retrospective Studies	2019
[Therapeutic and pharmacologic perspectives in Parkinson's disease]. La Revue du praticien, 2018, Volume: 68, Issue:5 Topics: Antiparkinson Agents; Disease Progression; Dyskinesias; Humans; Levodopa; Parkinson Disease	2018
Perspectives on the Earlier Use of Deep Brain Stimulation for Parkinson Disease from a Qualitative Study of U.S. Clinicians. World neurosurgery, 2019, Volume: 128 Topics: Antiparkinson Agents; Attitude of Health Personnel; Deep Brain Stimulation; Disease Progression; Early Medical Intervention; Female; Humans; Levodopa; Male; Neurologists; Neurosurgeons; Parkinson Disease; Patient Selection; Pilot Projects; Qualitative Research; Quality of Life; Severity of Illness Index; Time Factors	2019
Late-onset presentation of POLG1-associated mitochondrial disease. BMJ case reports, 2019, Mar-31, Volume: 12, Issue:3 Topics: Age of Onset; Aged; Antiparkinson Agents; Blepharoptosis; Disease Progression; DNA Polymerase gamma; Humans; Levodopa; Male; Mitochondrial Diseases; Ophthalmoplegia, Chronic Progressive External; Parkinsonian Disorders; Point Mutation; Treatment Outcome	2019
Axial symptoms predict mortality in patients with Parkinson disease and subthalamic stimulation. Neurology, 2019, 05-28, Volume: 92, Issue:22 Topics: Antiparkinson Agents; Deep Brain Stimulation; Disability Evaluation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Prognosis; Subthalamic Nucleus	2019
L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression. Parkinsonism & related disorders, 2019, Volume: 65 Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Mental Status and Dementia Tests; Middle Aged; Parkinson Disease; Severity of Illness Index; Treatment Outcome	2019
Early- vs late-start levodopa relieved symptoms but did not affect disease progression in Parkinson disease. Annals of internal medicine, 2019, 05-21, Volume: 170, Issue:10 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease	2019
Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's disease. Journal of the neurological sciences, 2019, Jul-15, Volume: 402 Topics: Affect; Aged; Antidepressive Agents; Antiparkinson Agents; Cognition; Depression; Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Treatment Outcome	2019
White matter hyperintensities as a predictor of freezing of gait in Parkinson's disease. Parkinsonism & related disorders, 2019, Volume: 66 Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Prognosis; Retrospective Studies; White Matter	2019
Levodopa changes the severity of freezing in Parkinson's disease. Parkinsonism & related disorders, 2013, Volume: 19, Issue:10 Topics: Adult; Aged; Antiparkinson Agents; Biomechanical Phenomena; Cognition; Disease Progression; Dose-Response Relationship, Drug; Female; Gait; Humans; Levodopa; Male; Neuropsychological Tests; Parkinson Disease	2013
Deep brain stimulation of the subthalamic nucleus for peripherally induced parkinsonism. Neuromodulation : journal of the International Neuromodulation Society, 2014, Volume: 17, Issue:1 Topics: Adult; Antiparkinson Agents; Cholinergic Antagonists; Combined Modality Therapy; Deep Brain Stimulation; Disease Progression; Dopamine Agonists; Drug Resistance; Drug Therapy, Combination; Humans; Levodopa; Magnetic Resonance Imaging; Male; Neuronal Plasticity; Pallidotomy; Parkinson Disease, Secondary; Severity of Illness Index; Shoulder Injuries; Subthalamic Nucleus	2014
[Copper intoxication decreases lifespan and induces neurologic alterations in Drosophila melanogaster]. Investigacion clinica, 2013, Volume: 54, Issue:1 Topics: Age Factors; Animals; Copper Sulfate; Disease Models, Animal; Disease Progression; Dopamine Agents; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Dopaminergic Neurons; Drosophila melanogaster; Female; Fluphenazine; Hepatolenticular Degeneration; Humans; Levodopa; Longevity; Male; Motor Activity; Sampling Studies; Synaptic Transmission	2013
The timing between REM sleep behavior disorder and Parkinson's disease. Sleep & breathing = Schlaf & Atmung, 2014, Volume: 18, Issue:2 Topics: Aged; Cognition Disorders; Disease Progression; Dopamine Agents; Dose-Response Relationship, Drug; Electromyography; Female; Humans; Levodopa; Male; Mental Status Schedule; Middle Aged; Parkinson Disease; Polysomnography; REM Sleep Behavior Disorder; Time Factors	2014
Cerebellar and parkinsonian phenotypes in multiple system atrophy: similarities, differences and survival. Journal of neural transmission (Vienna, Austria : 1996), 2014, Volume: 121, Issue:5 Topics: Age of Onset; Anti-Dyskinesia Agents; Brain; Disease Progression; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Motor Activity; Multiple System Atrophy; Phenotype; Prevalence; Prognosis; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome	2014
Imaging of the dopamine transporter predicts pattern of disease progression and response to levodopa in patients with schizophrenia and parkinsonism: a 2-year follow-up multicenter study. Schizophrenia research, 2014, Volume: 152, Issue:2-3 Topics: Adult; Age Factors; Aged; Chi-Square Distribution; Disease Progression; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinsonian Disorders; Predictive Value of Tests; Protein Binding; Schizophrenia; Severity of Illness Index; Tomography, Emission-Computed, Single-Photon; Tropanes	2014
Asymmetric postural tremor preceding DOPA-responsive Parkinsonism - the transition disease. Journal of Parkinson's disease, 2014, Volume: 4, Issue:1 Topics: Aged; Brain; Disease Progression; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Posture; Prospective Studies; Tremor	2014
Long-term levodopa/carbidopa intestinal gel in advanced Parkinson's disease. Journal of neurology, 2014, Volume: 261, Issue:3 Topics: Aged; Antiparkinson Agents; Carbidopa; Cognition Disorders; Cognitive Dysfunction; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Gastrostomy; Gels; Humans; Infusions, Parenteral; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Treatment Outcome	2014
A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease. Synapse (New York, N.Y.), 2014, Volume: 68, Issue:8 Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tyrosine	2014
The modern pre-levodopa era of Parkinson's disease: insights into motor complications from sub-Saharan Africa. Brain : a journal of neurology, 2014, Volume: 137, Issue:Pt 10 Topics: Adult; Africa South of the Sahara; Age of Onset; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cross-Sectional Studies; Data Interpretation, Statistical; Disease Progression; Dyskinesia, Drug-Induced; Female; Ghana; Humans; Italy; Levodopa; Longitudinal Studies; Male; Middle Aged; Neurologic Examination; Parkinson Disease; Prospective Studies; Young Adult	2014
Restricted disease propagation in multiple system atrophy with prolonged survival. Neuropathology and applied neurobiology, 2015, Volume: 41, Issue:5 Topics: Aged, 80 and over; Brain; Disease Progression; Fatal Outcome; Female; Humans; Levodopa; Multiple System Atrophy	2015
Does idiopathic restless legs syndrome delay onset and reduce severity of Parkinson's disease: a pilot study. The International journal of neuroscience, 2015, Volume: 125, Issue:7 Topics: Age Factors; Aged; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Humans; Levodopa; Logistic Models; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pilot Projects; Restless Legs Syndrome; Severity of Illness Index	2015
Towards an expert system for accurate diagnosis and progress monitoring of Parkinson's disease. Advances in experimental medicine and biology, 2015, Volume: 822 Topics: Algorithms; Antiparkinson Agents; Biomarkers; Carbidopa; Deep Brain Stimulation; Disease Progression; Drug Therapy, Combination; Expert Systems; Humans; Levodopa; Parkinson Disease; Sensitivity and Specificity	2015
Progression of gait dysfunction in incident Parkinson's disease: impact of medication and phenotype. Movement disorders : official journal of the Movement Disorder Society, 2015, Volume: 30, Issue:3 Topics: Aged; Cognition Disorders; Cohort Studies; Disability Evaluation; Disease Progression; Dopamine Agents; Female; Gait Disorders, Neurologic; Humans; Incidence; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Phenotype; Walking	2015
Evidence of an association between sleep and levodopa-induced dyskinesia in an animal model of Parkinson's disease. Neurobiology of aging, 2015, Volume: 36, Issue:3 Topics: Animals; Disease Models, Animal; Disease Progression; Dyskinesia, Drug-Induced; Homeostasis; Levodopa; Male; Neuronal Plasticity; Parkinson Disease; Rats, Sprague-Dawley; Sleep; Sleep Deprivation	2015
Speech rate in Parkinson's disease: A controlled study. Neurologia (Barcelona, Spain), 2016, Volume: 31, Issue:7 Topics: Adult; Aged; Antiparkinson Agents; Articulation Disorders; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Speech	2016
Toward Understanding Ambulatory Activity Decline in Parkinson Disease. Physical therapy, 2015, Volume: 95, Issue:8 Topics: Aged; Antiparkinson Agents; Disability Evaluation; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Levodopa; Longitudinal Studies; Male; Mobility Limitation; Parkinson Disease; Postural Balance; Prospective Studies; Quality of Life; Self Efficacy; Surveys and Questionnaires; Upper Extremity	2015
Progressive supra-nuclear palsy: frequency of cardinal extrapyramidal features at first presentation. Postgraduate medical journal, 2015, Volume: 91, Issue:1075 Topics: Accidental Falls; Aged; Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Early Diagnosis; Female; Humans; India; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Posture; Practice Guidelines as Topic; Prevalence; Supranuclear Palsy, Progressive	2015
One-year Outcome of Bilateral Subthalamic Stimulation in Parkinson Disease: An Eastern Experience. World neurosurgery, 2015, Volume: 84, Issue:5 Topics: Adult; Aged; Antiparkinson Agents; Cohort Studies; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Postoperative Complications; Retrospective Studies; Speech Disorders; Subthalamic Nucleus; Taiwan; Treatment Outcome	2015
Abnormal Olfaction in Parkinson's Disease Is Related to Faster Disease Progression. Behavioural neurology, 2015, Volume: 2015 Topics: Aged; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Smell; Surveys and Questionnaires; Treatment Outcome	2015
[Parkinson's disease associated with a mutation in the PARK2 gene]. Duodecim; laaketieteellinen aikakauskirja, 2015, Volume: 131, Issue:12 Topics: Age of Onset; Disease Progression; Finland; Genotype; Humans; Levodopa; Mutation; Parkinson Disease; Phenotype; Ubiquitin-Protein Ligases	2015
Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease. IEEE journal of biomedical and health informatics, 2015, Volume: 19, Issue:6 Topics: Aged; Disease Progression; Female; Humans; Internet; Levodopa; Male; Middle Aged; Parkinson Disease; Telemedicine; Telemetry; User-Computer Interface	2015
Articulation disorders and duration, severity and L-dopa dosage in idiopathic Parkinson's disease. Neurologia i neurochirurgia polska, 2015, Volume: 49, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Articulation Disorders; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Jaw; Levodopa; Lip; Male; Middle Aged; Parkinson Disease; Phonation; Phonetics; Range of Motion, Articular; Reflex, Abnormal; Respiration; Severity of Illness Index	2015
Delayed chorea after recovery from severe akinetic-rigid parkinsonism caused by extrapontine myelinolysis. Journal of the neurological sciences, 2015, Nov-15, Volume: 358, Issue:1-2 Topics: Carbidopa; Chorea; Disease Progression; Dopamine Agonists; Drug Combinations; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Myelinolysis, Central Pontine; Parkinsonian Disorders	2015
Changes in plasma catecholamines levels as preclinical biomarkers in experimental models of Parkinson's disease. Doklady. Biochemistry and biophysics, 2015, Volume: 464 Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Biomarkers; Blood Chemical Analysis; Chromatography, High Pressure Liquid; Disease Progression; Dopamine; Epinephrine; Levodopa; Male; Mice, Inbred C57BL; MPTP Poisoning; Norepinephrine; Prodromal Symptoms; Severity of Illness Index	2015
[Pain fluctuations in Parkinson's disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:9 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain; Pain Measurement; Parkinson Disease	2015
Risk and course of motor complications in a population-based incident Parkinson's disease cohort. Parkinsonism & related disorders, 2016, Volume: 22 Topics: Age Factors; Aged; Antiparkinson Agents; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Dyskinesias; Female; Humans; Incidence; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Movement Disorders; Norway; Parkinson Disease; Proportional Hazards Models; Prospective Studies; Risk Factors; Sex Factors; Superior Sagittal Sinus	2016
The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2016, Volume: 37, Issue:5 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Parkinson Disease; Severity of Illness Index; Statistics, Nonparametric; Uric Acid	2016
Study of levodopa response in Parkinson's disease: Observations on rates of motor progression. Movement disorders : official journal of the Movement Disorder Society, 2016, Volume: 31, Issue:4 Topics: Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Outcome Assessment, Health Care; Parkinson Disease; Severity of Illness Index	2016
Work and power reduced in L-dopa naïve patients in the early-stages of Parkinson's disease. Arquivos de neuro-psiquiatria, 2016, Volume: 74, Issue:4 Topics: Activities of Daily Living; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Humans; Levodopa; Lower Extremity; Male; Middle Aged; Motor Activity; Muscle Strength; Muscle Strength Dynamometer; Parkinson Disease; Reference Values; Statistics, Nonparametric; Time Factors; Torso	2016
Effects of Levodopa on Postural Strategies in Parkinson's disease. Gait & posture, 2016, Volume: 46 Topics: Adult; Aged; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Postural Balance; Posture	2016
A Novel Homozygous p.L539F Mutation Identified in PINK1 Gene in a Moroccan Patient with Parkinsonism. BioMed research international, 2016, Volume: 2016 Topics: Amino Acid Motifs; Chromosomes; Cognition Disorders; Computational Biology; Disease Progression; Exons; Homozygote; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Morocco; Mutation; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Parkinson Disease; Pedigree; Phenotype; Protein Domains; Protein Kinases; Sequence Analysis, DNA	2016
The non-motor side of the honeymoon period of Parkinson's disease and its relationship with quality of life: a 4-year longitudinal study. European journal of neurology, 2016, Volume: 23, Issue:11 Topics: Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Quality of Life; Severity of Illness Index; Sex Factors; Symptom Assessment	2016
Status dystonicus in children: Early recognition and treatment prevent serious complications. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2016, Volume: 20, Issue:6 Topics: Adolescent; Anti-Dyskinesia Agents; Athetosis; Baclofen; Cerebral Palsy; Child; Disease Progression; Dystonia; Female; Fluid Therapy; Humans; Infections; Levodopa; Male; Muscle Relaxants, Central; Retrospective Studies; Treatment Outcome	2016
Caffeine consumption and the 4-year progression of de novo Parkinson's disease. Parkinsonism & related disorders, 2016, Volume: 32 Topics: Aged; Antiparkinson Agents; Caffeine; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Proportional Hazards Models; Quality of Life; Surveys and Questionnaires; Time Factors	2016
Two hundred steps. Nature, 2016, 10-27, Volume: 538, Issue:7626 Topics: alpha-Synuclein; Creatine; Deep Brain Stimulation; Disease Progression; Dopamine; Fetal Tissue Transplantation; History, 19th Century; History, 20th Century; History, 21st Century; Humans; Levodopa; Lewy Bodies; Neostriatum; Neurons; Parkinson Disease; Parkinson Disease, Postencephalitic; Prion Diseases; Substantia Nigra; Thalamus	2016
Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochemistry international, 2017, Volume: 105 Topics: Aged; Antiparkinson Agents; Biomarkers; Disease Progression; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease	2017
Octogenarian parkinsonism - Clinicopathological observations. Parkinsonism & related disorders, 2017, Volume: 37 Topics: Aged, 80 and over; Aging; Antiparkinson Agents; Autopsy; Brain; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Parkinsonian Disorders	2017
Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease. International journal of molecular sciences, 2017, Jan-24, Volume: 18, Issue:2 Topics: Aged; Alleles; Animals; Disease Progression; Dyskinesias; Female; Genetic Predisposition to Disease; Genotype; Humans; Kaplan-Meier Estimate; Levodopa; Male; Middle Aged; Parkinson Disease; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Receptors, Dopamine	2017
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism & related disorders, 2017, Volume: 38 Topics: Antiparkinson Agents; Carbidopa; Disease Progression; Drug Combinations; Female; Gels; Health Surveys; Humans; Intestines; Italy; Levodopa; Longitudinal Studies; Male; Parkinson Disease; Retrospective Studies; Substance Withdrawal Syndrome	2017
Levodopa, motor complications and disease progression. Journal of the neurological sciences, 2008, Oct-15, Volume: 273, Issue:1-2 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Movement Disorders; Parkinson Disease	2008
[Subacute worsening of rigidity in a patient with Parkinson disease]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2008, Sep-25, Volume: 128, Issue:18 Topics: Aged; Antiparkinson Agents; Brain Neoplasms; Disease Progression; Glioblastoma; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle Rigidity; Muscle Spasticity; Parkinson Disease	2008
UPDRS activity of daily living score as a marker of Parkinson's disease progression. Movement disorders : official journal of the Movement Disorder Society, 2009, Jan-30, Volume: 24, Issue:2 Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cross-Sectional Studies; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Psychomotor Performance; Treatment Outcome	2009
Cardiac MIBG scintigraphy in Primary Progressive Freezing Gait. Parkinsonism & related disorders, 2009, Volume: 15, Issue:5 Topics: 3-Iodobenzylguanidine; Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Female; Gait; Gait Apraxia; Heart; Humans; Iodine Radioisotopes; Levodopa; Male; Middle Aged; Parkinson Disease; Radionuclide Imaging; Radiopharmaceuticals; Reference Values; Treatment Outcome	2009
Pallidal deep brain stimulation and L-dopa effect on PET motor activation in advanced Parkinson's disease. Journal of neuroimaging : official journal of the American Society of Neuroimaging, 2009, Volume: 19, Issue:3 Topics: Analysis of Variance; Antiparkinson Agents; Brain; Brain Mapping; Butanols; Deep Brain Stimulation; Disease Progression; Female; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Motor Activity; Oxygen Radioisotopes; Parkinson Disease; Positron-Emission Tomography; Reaction Time; Task Performance and Analysis	2009
Development of Holmes' tremor in a patient with Parkinson's disease following acute cerebellar infarction. Movement disorders : official journal of the Movement Disorder Society, 2009, Feb-15, Volume: 24, Issue:3 Topics: Acute Disease; Aged, 80 and over; Antiparkinson Agents; Cerebellum; Cerebral Infarction; Disease Progression; Female; Humans; Levodopa; Parkinson Disease; Severity of Illness Index; Tremor	2009
The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: association with ferritin levels. Sleep medicine, 2009, Volume: 10, Issue:6 Topics: Aged; Biomarkers; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Ferritins; Humans; Levodopa; Male; Middle Aged; Prospective Studies; Restless Legs Syndrome; Severity of Illness Index; Sleep Wake Disorders	2009
Altered platelet monoamine oxidase-B activity in idiopathic Parkinson's disease. Neurochemical research, 2009, Volume: 34, Issue:8 Topics: Adult; Aged; Amantadine; Antiparkinson Agents; Blood Platelets; Disease Progression; Female; Humans; India; Levodopa; Male; Middle Aged; Monoamine Oxidase; Parkinson Disease; Young Adult	2009
A follow-up study on 6-[18F]fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Movement disorders : official journal of the Movement Disorder Society, 2009, May-15, Volume: 24, Issue:7 Topics: Aged; Brain Mapping; Disease Progression; Female; Fluorodeoxyglucose F18; Functional Laterality; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Nonlinear Dynamics; Parkinson Disease; Positron-Emission Tomography; Postmortem Changes; Putamen; Time Factors	2009
Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. Journal of neurology, neurosurgery, and psychiatry, 2009, Volume: 80, Issue:8 Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Disease Progression; Dopamine Agents; Dystonia; Female; GTP Cyclohydrolase; Hormones; Humans; Levodopa; Long-Term Care; Male; Mental Disorders; Middle Aged; Mutation; Treatment Outcome; Young Adult	2009
Onset and spread of dyskinesias and motor symptoms in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2009, Oct-30, Volume: 24, Issue:14 Topics: Age of Onset; Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Hand Strength; Humans; Italy; Levodopa; Male; Middle Aged; Motor Skills; Movement; Movement Disorders; Parkinson Disease; Retrospective Studies	2009
Conjugal Parkinsonism and Parkinson disease: a case series with environmental risk factor analysis. Parkinsonism & related disorders, 2010, Volume: 16, Issue:3 Topics: Age of Onset; Aged; Cognition Disorders; Disease Progression; Environment; Environmental Exposure; Female; Humans; Levodopa; Male; Marriage; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Risk Assessment; Risk Factors; Surveys and Questionnaires	2010
ADAGIO misses a beat? The Lancet. Neurology, 2009, Volume: 8, Issue:12 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Research Design; Rosiglitazone; Thiazolidinediones; United States; United States Food and Drug Administration	2009
Oxidative damage in Parkinson disease: Measurement using accurate biomarkers. Free radical biology & medicine, 2010, Feb-15, Volume: 48, Issue:4 Topics: Aged; Biomarkers; C-Reactive Protein; Case-Control Studies; Cholesterol; Disease Progression; DNA; F2-Isoprostanes; Female; Humans; Hydroxyeicosatetraenoic Acids; Levodopa; Lipids; Male; Middle Aged; Oxidative Stress; Oxygen; Parkinson Disease	2010
MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease. Genes, brain, and behavior, 2010, Mar-01, Volume: 9, Issue:2 Topics: Animals; Base Pairing; Disease Progression; DNA Primers; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; High Mobility Group Proteins; Levodopa; Male; Mesencephalon; Mice; Mice, Knockout; Models, Genetic; Motor Activity; Parkinson Disease; Polymerase Chain Reaction; Posture	2010
Guideline for the treatment of Parkinson's disease. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2009, Volume: 99, Issue:10 Topics: Antiparkinson Agents; Cholinergic Antagonists; Disease Progression; Dopamine Agonists; Humans; Levodopa; Monoamine Oxidase Inhibitors; Parkinson Disease; Quality of Life	2009
Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study. Neurology, 2010, Apr-13, Volume: 74, Issue:15 Topics: Aged; Antiparkinson Agents; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Time Factors	2010
Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain : a journal of neurology, 2010, Volume: 133, Issue:Pt 6 Topics: Age of Onset; Amino Acid Metabolism, Inborn Errors; Brain; Brain Diseases; Catecholamines; Child, Preschool; Disease Progression; Dopamine Agents; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Hypokinesia; Infant; Levodopa; Muscle Rigidity; Mutation, Missense; Phenotype; Promoter Regions, Genetic; Severity of Illness Index; Tyrosine 3-Monooxygenase	2010
[Rapidly progressive parkinsonism that developed one year after ventriculoperitoneal shunting for idiopathic aqueductal stenosis: a case report]. Brain and nerve = Shinkei kenkyu no shinpo, 2010, Volume: 62, Issue:5 Topics: Acute Disease; Cerebral Aqueduct; Constriction, Pathologic; Disease Progression; Female; Humans; Levodopa; Middle Aged; Parkinsonian Disorders; Postoperative Complications; Syndrome; Treatment Outcome; Ventriculoperitoneal Shunt	2010
Levodopa/benserazide-loaded biodegradable microspheres reduce dyskinesia in rats. Neuroreport, 2010, Aug-23, Volume: 21, Issue:12 Topics: Animals; Antiparkinson Agents; Benserazide; Biocompatible Materials; Disease Models, Animal; Disease Progression; Drug Combinations; Drug Synergism; Dyskinesia, Drug-Induced; Female; Lameness, Animal; Levodopa; Microspheres; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Treatment Outcome	2010
Clinical features associated with REM sleep behavior disorder symptoms in the early stages of Parkinson's disease. Journal of neurology, 2011, Volume: 258, Issue:1 Topics: Aged; Antiparkinson Agents; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Disease Progression; Female; Hallucinations; Humans; Levodopa; Male; Movement; Parkinson Disease; Polysomnography; Prognosis; REM Sleep Behavior Disorder; Surveys and Questionnaires; Tremor	2011
Treatment of advanced Parkinson's disease in the United States: a cost-utility model. Clinical drug investigation, 2010, Volume: 30, Issue:11 Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States	2010
Impairments in social cognition in early medicated and unmedicated Parkinson disease. Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology, 2010, Volume: 23, Issue:3 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Case-Control Studies; Cognition; Disease Progression; Executive Function; Humans; Levodopa; Matched-Pair Analysis; Middle Aged; Neuropsychological Tests; Parkinson Disease; Reference Values; Social Perception; Statistics, Nonparametric; Theory of Mind; Time Factors	2010
Motor complications in Parkinson's disease: ten year follow-up study. Movement disorders : official journal of the Movement Disorder Society, 2010, Dec-15, Volume: 25, Issue:16 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Severity of Illness Index; Statistics, Nonparametric	2010
Lack of motor symptoms progression in Parkinson's disease patients with long-term bilateral subthalamic deep brain stimulation. The International journal of neuroscience, 2010, Volume: 120, Issue:11 Topics: Aged; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome; Tremor	2010
Living with advanced Parkinson's disease: a constant struggle with unpredictability. Journal of advanced nursing, 2011, Volume: 67, Issue:2 Topics: Activities of Daily Living; Adaptation, Psychological; Adult; Aged; Attitude to Health; Chronic Disease; Deep Brain Stimulation; Disease Progression; Drug Administration Schedule; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Nursing Methodology Research; Parkinson Disease; Qualitative Research	2011
Dementia in Parkinson's disease: a 20-year neuropsychological study (Sydney Multicentre Study). Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:9 Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Cognition; Cohort Studies; Dementia; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Memory; Middle Aged; Neurologic Examination; Neuropsychological Tests; New South Wales; Parkinson Disease; Survival Analysis	2011
The natural history of treated Parkinson's disease in an incident, community based cohort. Journal of neurology, neurosurgery, and psychiatry, 2011, Volume: 82, Issue:10 Topics: Age Factors; Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Genotype; Haplotypes; Humans; Kaplan-Meier Estimate; Levodopa; Male; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Quality of Life; tau Proteins	2011
Severe weight loss in a young Parkinson's disease patient: a multidisciplinary approach to diagnosis and treatment. The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:3 Topics: Antiparkinson Agents; Carbidopa; Caregivers; Disease Progression; Domestic Violence; Drug Combinations; Eating; Female; Humans; Hypertrichosis; Levodopa; Middle Aged; Nutritional Status; Parkinson Disease; Weight Loss	2011
Gait disturbances in Parkinson disease. Did freezing of gait exist before levodopa? Historical review. Journal of the neurological sciences, 2011, Aug-15, Volume: 307, Issue:1-2 Topics: Antiparkinson Agents; Disease Progression; Gait Disorders, Neurologic; History, 19th Century; Humans; Levodopa; Parkinson Disease	2011
Deep brain stimulation in benign tremulous parkinsonism. Archives of neurology, 2011, Volume: 68, Issue:8 Topics: Adult; Aged; Cohort Studies; Deep Brain Stimulation; Disease Progression; Drug Resistance; Essential Tremor; Female; Humans; Levodopa; Male; Middle Aged; Parkinsonian Disorders; Patient Selection; Retrospective Studies; Subthalamic Nucleus; Treatment Outcome; Tremor; Ventral Thalamic Nuclei	2011
Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. Journal of Zhejiang University. Science. B, 2011, Volume: 12, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Cluster Analysis; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Models, Statistical; Parkinson Disease; Phenotype; Quality of Life; Treatment Outcome	2011
Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease. Hiroshima journal of medical sciences, 2011, Volume: 60, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Aromatic Amino Acid Decarboxylase Inhibitors; Benserazide; Biomarkers; Carbidopa; Catechol O-Methyltransferase; Catechol O-Methyltransferase Inhibitors; Catechols; Disease Progression; Dopa Decarboxylase; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Japan; Levodopa; Male; Middle Aged; Motor Activity; Nitriles; Parkinson Disease; Prospective Studies; Treatment Outcome; Tyrosine	2011
Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons. Neurobiology of disease, 2012, Volume: 45, Issue:3 Topics: alpha-Synuclein; Amphetamine; Analysis of Variance; Animals; Antiparkinson Agents; Behavioral Symptoms; Cell Count; Chromatography, High Pressure Liquid; Dependovirus; Disease Models, Animal; Disease Progression; Dopamine; Dopaminergic Neurons; ELAV Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation; Genetic Vectors; Green Fluorescent Proteins; Humans; Levodopa; Mesencephalon; Nerve Tissue Proteins; Neurodegenerative Diseases; Parkinson Disease; Rats; Rats, Sprague-Dawley; Regulatory Elements, Transcriptional; Stereotyped Behavior; Time Factors; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins	2012
Hypokinesia without decrement distinguishes progressive supranuclear palsy from Parkinson's disease. Brain : a journal of neurology, 2012, Volume: 135, Issue:Pt 4 Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Case-Control Studies; Cognition; Disease Progression; Dopamine Agents; Female; Fingers; Handwriting; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Psychomotor Performance; Supranuclear Palsy, Progressive	2012
Treatment of Parkinson disease: a 64-year-old man with motor complications of advanced Parkinson disease. JAMA, 2012, Jun-06, Volume: 307, Issue:21 Topics: Amantadine; Antiparasitic Agents; Carbidopa; Catechols; Decision Making; Deep Brain Stimulation; Disease Progression; Dyskinesia, Drug-Induced; Gait Disorders, Neurologic; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Nitriles; Parkinson Disease; Quality of Life; Subthalamus	2012
Subthalamic activity during diphasic dyskinesias in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2012, Volume: 27, Issue:9 Topics: Aged; Antiparkinson Agents; Apomorphine; Cohort Studies; Deep Brain Stimulation; Disease Progression; Dyskinesias; Electrodes, Implanted; Female; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Neurosurgical Procedures; Parkinson Disease; Subthalamic Nucleus; Theta Rhythm	2012
Profile of multiple system atrophy in Moroccan patients attending a movement disorders outpatient clinic in Rabat university hospital. Revue neurologique, 2013, Volume: 169, Issue:2 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Amantadine; Disease Progression; Dopamine Agonists; Female; Hospitals, University; Humans; Hypotension, Orthostatic; Levodopa; Magnetic Resonance Imaging; Male; Mental Disorders; Middle Aged; Morocco; Movement Disorders; Multiple System Atrophy; Outpatient Clinics, Hospital; Phenotype; Retrospective Studies; Sleep Disorders, Intrinsic; Symptom Assessment; Urination Disorders	2013
Effect of L-ascorbic Acid on the climbing ability and protein levels in the brain of Drosophila model of Parkinson's disease. The International journal of neuroscience, 2012, Volume: 122, Issue:12 Topics: Age Factors; alpha-Synuclein; Animals; Animals, Genetically Modified; Antioxidants; Antiparkinson Agents; Ascorbic Acid; Brain; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drosophila; Drosophila Proteins; Gait Disorders, Neurologic; Humans; Levodopa; Membrane Proteins; Neurons; Parkinson Disease; Transcription Factors	2012
Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease. Parkinsonism & related disorders, 2012, Volume: 18, Issue:10 Topics: Aged; Amantadine; Antidepressive Agents; Antiparkinson Agents; Data Collection; Depression; Disease Progression; Disruptive, Impulse Control, and Conduct Disorders; Dopamine Agonists; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Risk Factors; Self Report; Sex Distribution; Surveys and Questionnaires	2012
Long-duration Parkinson's disease: role of lateralization of motor features. Parkinsonism & related disorders, 2013, Volume: 19, Issue:1 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Case-Control Studies; Dementia; Disease Progression; Female; Functional Laterality; Humans; Levodopa; Longevity; Male; Middle Aged; Parkinson Disease; REM Sleep Behavior Disorder; Tremor	2013
Longitudinal study of levodopa in Parkinson's disease: effects of the advanced disease phase. Movement disorders : official journal of the Movement Disorder Society, 2013, Volume: 28, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Dementia; Disease Progression; Female; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Motor Activity; Parkinson Disease; Prospective Studies; Subthalamic Nucleus; Treatment Outcome	2013
Melanoma progression and serum L-dopa/L-tyrosine ratio: a comparison with S100B. Melanoma research, 2002, Volume: 12, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Bulgaria; Chromatography, High Pressure Liquid; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Melanoma; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Nerve Growth Factors; Predictive Value of Tests; Prognosis; S100 Calcium Binding Protein beta Subunit; S100 Proteins; Skin Neoplasms; Tyrosine	2002
The natural history of the syndrome of primary progressive freezing gait. Archives of neurology, 2002, Volume: 59, Issue:11 Topics: Aged; Aged, 80 and over; Cohort Studies; Diagnosis, Differential; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Radiography; Retrospective Studies; Syndrome	2002
Reversal of parkinsonism following liver transplantation. Neurology, 2003, Feb-11, Volume: 60, Issue:3 Topics: Acute Disease; Aged; Antiparkinson Agents; Carbidopa; Disease Progression; Gait Disorders, Neurologic; Humans; Immunosuppressive Agents; Levodopa; Liver Cirrhosis; Liver Transplantation; Male; Parkinsonian Disorders; Remission Induction; Treatment Outcome; Tremor	2003
Two large Polish kindreds with levodopa-responsive Parkinsonism not linked to known Parkinsonian genes and loci. Parkinsonism & related disorders, 2003, Volume: 9, Issue:4 Topics: Activities of Daily Living; Adult; Age of Onset; Aged; Antiparkinson Agents; Dementia; Disease Progression; Female; Genetic Linkage; Humans; Levodopa; Male; Middle Aged; Molecular Biology; Parkinsonian Disorders; Pedigree; Phenotype; Poland; Urinary Incontinence	2003
Parkinson disease with old-age onset: a comparative study with subjects with middle-age onset. Archives of neurology, 2003, Volume: 60, Issue:4 Topics: Adult; Age of Onset; Aged; Antiparkinson Agents; Case-Control Studies; Comorbidity; Databases, Factual; Disease Progression; Female; Humans; Levodopa; Logistic Models; Male; Middle Aged; Odds Ratio; Parkinson Disease; Prevalence; Risk Assessment; Risk Factors; Severity of Illness Index	2003
REAL and CALM: what have we learned? Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:7 Topics: Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Corpus Striatum; Disease Progression; Dopamine; Feasibility Studies; Humans; Indoles; Levodopa; Neurons; Neuroprotective Agents; Parkinson Disease; Pramipexole; Putamen; Reference Values; Sensitivity and Specificity; Thiazoles; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon	2003
Gaucher's disease with Parkinson's disease: clinical and pathological aspects. Neurology, 2003, Jul-08, Volume: 61, Issue:1 Topics: Adult; Age of Onset; Aged; Anemia; Antiparkinson Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance; Female; Gaucher Disease; Glucosylceramidase; Hepatomegaly; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Muscle Rigidity; Parkinson Disease; Recombinant Proteins; Siblings; Splenomegaly; Thrombocytopenia; Tremor	2003
Cabergoline versus levodopa monotherapy: a decision analysis. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:8 Topics: Antiparkinson Agents; Cabergoline; Cost-Benefit Analysis; Decision Making; Disease Progression; Ergolines; Female; Humans; Levodopa; Male; Markov Chains; Middle Aged; Parkinson Disease; Severity of Illness Index	2003
How much phenotypic variation can be attributed to parkin genotype? Annals of neurology, 2003, Volume: 54, Issue:2 Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Exons; Female; Genetic Variation; Genotype; Heterozygote; Humans; Levodopa; Male; Middle Aged; Mutation; Mutation, Missense; Parkinson Disease; Phenotype; Ubiquitin-Protein Ligases	2003
Heart rate variability and Parkinson's disease severity. Journal of neural transmission (Vienna, Austria : 1996), 2003, Volume: 110, Issue:9 Topics: Autonomic Nervous System Diseases; Cardiovascular System; Chronobiology Disorders; Disease Progression; Female; Heart Rate; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Surveys and Questionnaires; Sympathetic Nervous System; Up-Regulation; Vagus Nerve	2003
Clinical criteria for the switch of treatment strategies in Parkinson's disease. Clinical neurology and neurosurgery, 2003, Volume: 105, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Patient Care Planning; Prognosis; Retrospective Studies; Severity of Illness Index	2003
[Diagnosis and therapy for patients with Parkinson's disease (discussion)]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2003, Aug-10, Volume: 92, Issue:8 Topics: Autonomic Nervous System Diseases; Disease Progression; Dopamine Agonists; Gait Disorders, Neurologic; Humans; Levodopa; Life Style; Low Back Pain; Mental Disorders; Neurosurgical Procedures; Parkinson Disease; Stereotaxic Techniques	2003
Parkinson's disease, subthalamic stimulation, and selection of candidates: a pathological study. Movement disorders : official journal of the Movement Disorder Society, 2003, Volume: 18, Issue:12 Topics: Aged; Antiparkinson Agents; Cognition Disorders; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Fatal Outcome; Female; Humans; Levodopa; Neuropsychological Tests; Parkinson Disease; Subthalamic Nucleus; Tremor	2003
Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology, 2004, Jan-27, Volume: 62, Issue:2 Topics: Antiparkinson Agents; Artifacts; Benzothiazoles; Clinical Trials as Topic; Disease Progression; Dopamine Agonists; Humans; Levodopa; Parkinson Disease; Pramipexole; Severity of Illness Index; Single-Blind Method; Thiazoles	2004
Exercise-induced dystonia as a preceding symptom of familial Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2004, Volume: 19, Issue:2 Topics: Aged; Antiparkinson Agents; Carbidopa; Disease Progression; DNA Mutational Analysis; Drug Combinations; Dystonic Disorders; Exercise; Female; Genotype; Humans; Levodopa; Male; Middle Aged; Neurologic Examination; Parkinsonian Disorders; Phenotype; Semen; Ubiquitin-Protein Ligases; Videotape Recording	2004
Essential tremor course and disability: A clinicopathologic study of 20 cases. Neurology, 2004, Mar-23, Volume: 62, Issue:6 Topics: Adrenergic beta-Antagonists; Age of Onset; Aged; Antiparkinson Agents; Disability Evaluation; Disease Progression; Essential Tremor; Female; Humans; Levodopa; Lewy Body Disease; Male; Propranolol; Saskatchewan; Supranuclear Palsy, Progressive	2004
Alternating hemiplegia of childhood: presentation of two cases regarding the extent of variability. Epileptic disorders : international epilepsy journal with videotape, 2004, Volume: 6, Issue:1 Topics: Anticonvulsants; Cerebral Cortex; Child; Diagnosis, Differential; Disease Progression; Dose-Response Relationship, Drug; Drug Tolerance; Dystonia; Electroencephalography; Epilepsy, Partial, Motor; Epilepsy, Reflex; Female; Hemiplegia; Humans; Infant; Levodopa; Neurologic Examination; Status Epilepticus; Sudden Infant Death	2004
Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment. Experimental neurology, 2004, Volume: 187, Issue:1 Topics: Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Disease Models, Animal; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Heterozygote; Homozygote; Islands of Calleja; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Neostriatum; Nerve Tissue Proteins; Nucleus Accumbens; Olfactory Pathways; Oxidative Stress; Parkinsonian Disorders; Prosencephalon; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Receptor, trkB; Receptors, Dopamine D2; Receptors, Dopamine D3; RNA, Messenger; Tyrosine 3-Monooxygenase	2004
Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain : a journal of neurology, 2004, Volume: 127, Issue:Pt 12 Topics: Aged; Analysis of Variance; Antiparkinson Agents; Caudate Nucleus; Disease Progression; Dopamine; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Putamen; Synapses	2004
Long-term course of L-dopa-responsive dystonia caused by tyrosine hydroxylase deficiency. Neurology, 2004, Oct-26, Volume: 63, Issue:8 Topics: Adult; Age of Onset; Brain; Brain Chemistry; Catecholamines; Disease Progression; DNA Mutational Analysis; Dopamine Agents; Dystonia; Heterozygote; Humans; Levodopa; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Panic Disorder; Point Mutation; Siblings; Time; Tyrosine 3-Monooxygenase	2004
A young onset Parkinson's patient: a case study. The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses, 2004, Volume: 36, Issue:5 Topics: Activities of Daily Living; Adult; Age of Onset; Amantadine; Antiparkinson Agents; Carbidopa; Combined Modality Therapy; Deep Brain Stimulation; Dibenzothiazepines; Disease Progression; Dyskinesias; Humans; Levodopa; Male; Motor Skills; Nurse's Role; Parkinson Disease; Patient Advocacy; Patient Education as Topic; Quality of Life; Quetiapine Fumarate; Rhabdomyolysis; Severity of Illness Index; Social Support; Treatment Outcome	2004
Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:2 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Bromocriptine; Dementia; Disease Progression; Dose-Response Relationship, Drug; Employment; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Mortality; Movement Disorders; Multicenter Studies as Topic; Neurologic Examination; Neuropsychological Tests; Parkinson Disease; Time Factors	2005
Analysis of the course of Parkinson's disease under dopaminergic therapy: performance of "fast tapping" is not a suitable parameter. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:3 Topics: Bromocriptine; Cross-Sectional Studies; Disease Progression; Dopamine Agonists; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease	2005
Effects of disease progression and L-dopa therapy on the control of reaching-grasping in Parkinson's disease. Neuropsychologia, 2005, Volume: 43, Issue:3 Topics: Aged; Antiparkinson Agents; Basal Ganglia; Biomechanical Phenomena; Case-Control Studies; Disease Progression; Female; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Severity of Illness Index; Task Performance and Analysis	2005
Treatment for the progression of Parkinson's disease. The Lancet. Neurology, 2005, Volume: 4, Issue:4 Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Parkinson Disease; Research Design	2005
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia. Experimental neurology, 2005, Volume: 194, Issue:1 Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal Ganglia; Buspirone; Disease Models, Animal; Disease Progression; Dopamine Agonists; Drug Administration Schedule; Dyskinesia, Drug-Induced; Indoles; Levodopa; Male; Mice; Mice, Inbred C57BL; Oxidopamine; Parkinsonian Disorders; Purines; Receptor, Adenosine A2A; Receptors, Dopamine D2; Reproducibility of Results; Riluzole; Treatment Outcome	2005
Camptocormia in a patient with multiple system atrophy. Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:8 Topics: Antiparkinson Agents; Cerebellum; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Movement Disorders; Multiple System Atrophy; Nerve Tissue Proteins; Oligodendroglia; Posture; Spinal Diseases; Synucleins	2005
Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD. Parkinsonism & related disorders, 2005, Volume: 11, Issue:6 Topics: Adult; Amino Acid Substitution; Antiparkinson Agents; Cognition; Disease Progression; Functional Laterality; Haplotypes; Humans; Ireland; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Levodopa; Male; Middle Aged; Mutation; Neuropsychological Tests; Parkinson Disease; Protein Serine-Threonine Kinases	2005
Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:2 Topics: Aged; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Levodopa; Metabolic Clearance Rate; Polysomnography; Restless Legs Syndrome; Spasm	2006
Absorption of orally disintegrating carbidopa-levodopa requires intact small bowel function. Neurology, 2005, Nov-08, Volume: 65, Issue:9 Topics: Administration, Oral; Aged; Carbidopa; Disease Progression; Dopamine Agents; Drug Combinations; Female; Humans; Intestinal Pseudo-Obstruction; Intestine, Small; Levodopa; Middle Aged; Parkinson Disease; Patient Selection; Substance Withdrawal Syndrome; Treatment Failure	2005
[The role of dopaminagonists in the treatment of Parkinson's disease]. Praxis, 2005, Oct-19, Volume: 94, Issue:42 Topics: Aged; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Levodopa; Long-Term Care; Neurologic Examination; Neuroprotective Agents; Parkinson Disease	2005
Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Movement disorders : official journal of the Movement Disorder Society, 2006, Volume: 21, Issue:5 Topics: Activities of Daily Living; Adult; Aged; Analysis of Variance; Antiparkinson Agents; Body Weight; Deep Brain Stimulation; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Activity; Motor Skills; Neuropsychological Tests; Parkinson Disease; Severity of Illness Index; Subthalamic Nucleus; Treatment Outcome	2006
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. Journal of neurology, neurosurgery, and psychiatry, 2005, Volume: 76, Issue:12 Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cognition Disorders; Deep Brain Stimulation; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Male; Middle Aged; Motor Skills Disorders; Parkinson Disease; Subthalamic Nucleus; Treatment Outcome	2005
Progression of Parkinson's disease following thalamic deep brain stimulation for tremor. Stereotactic and functional neurosurgery, 2005, Volume: 83, Issue:5-6 Topics: Aged; Deep Brain Stimulation; Disease Progression; Follow-Up Studies; Gait; Humans; Hypokinesia; Levodopa; Middle Aged; Motor Skills; Muscle Rigidity; Parkinson Disease; Severity of Illness Index; Thalamus; Tremor; Verbal Behavior	2005
Long-term clinical evaluation in patients with Parkinson's disease and early autonomic involvement. Parkinsonism & related disorders, 2006, Volume: 12, Issue:5 Topics: Aged; Antiparkinson Agents; Autonomic Nervous System; Bromocriptine; Disability Evaluation; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Follow-Up Studies; Hemodynamics; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Parkinson Disease; Pergolide; Prognosis; Survival Analysis	2006
[Subthalamic stimulation in a patient with multiple system atrophy: a clinicopathological report]. Revue neurologique, 2006, Volume: 162, Issue:3 Topics: Adenoma; alpha-Synuclein; Antiparkinson Agents; Biomarkers; Brain; Brain Chemistry; Combined Modality Therapy; Deep Brain Stimulation; Diagnostic Errors; Disease Progression; Fatal Outcome; Humans; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Parkinson Disease; Prostatectomy; Prostatic Neoplasms; Substantia Nigra; Subthalamic Nucleus; Ubiquitin	2006
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. Journal of pharmacokinetics and pharmacodynamics, 2006, Volume: 33, Issue:3 Topics: Algorithms; Antiparkinson Agents; Bayes Theorem; Bromocriptine; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Levodopa; Models, Biological; Parkinson Disease; Pergolide; Randomized Controlled Trials as Topic; Selegiline; Treatment Outcome	2006
Levodopa-induced alterations in speech rate in advanced Parkinson's disease. Acta neurologica Belgica, 2006, Volume: 106, Issue:1 Topics: Antiparkinson Agents; Articulation Disorders; Brain; Disease Progression; Dopamine; Female; Humans; Levodopa; Male; Neural Pathways; Parkinson Disease; Speech; Treatment Outcome	2006
After the diagnosis: living with Parkinson's. There's no cure for Parkinson's disease, but new treatments can ease the symptoms and prolong independence. Harvard women's health watch, 2006, Volume: 13, Issue:10 Topics: Antiparkinson Agents; Deep Brain Stimulation; Disease Progression; Drug Tolerance; Female; Humans; Levodopa; Neuroprotective Agents; Parkinson Disease	2006
Changes in gait and symptoms after bilateral pallidotomy: a client with Parkinson's disease. Physiotherapy research international : the journal for researchers and clinicians in physical therapy, 2006, Volume: 11, Issue:3 Topics: Antiparkinson Agents; Bromocriptine; Combined Modality Therapy; Disease Progression; Female; Gait; Globus Pallidus; Humans; Levodopa; Middle Aged; Pallidotomy; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome	2006
Motor fluctuations and dyskinesias in advanced/end stage Parkinson's disease: a study from a population of brain donors. Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:3 Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Brain; Cohort Studies; Disease Progression; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Nerve Degeneration; Neuronal Plasticity; Parkinson Disease; Synaptic Transmission; Tissue Donors	2007
Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias. Movement disorders : official journal of the Movement Disorder Society, 2007, Mar-15, Volume: 22, Issue:4 Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Disease Progression; Dopamine; Dyskinesias; Extremities; Levodopa; Male; Mesencephalon; Nerve Degeneration; Parkinson Disease; Prosencephalon; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Substantia Nigra; Tyrosine 3-Monooxygenase	2007
Prevalence and treatment strategies of dyskinesia in patients with Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2007, Volume: 114, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dyskinesias; Female; Germany; Humans; Interviews as Topic; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Retrospective Studies; Treatment Outcome	2007
Association of familial ataxia and restless legs syndrome. The Journal of neuropsychiatry and clinical neurosciences, 2007,Spring, Volume: 19, Issue:2 Topics: Adult; Antiparkinson Agents; Ataxia; Ataxin-3; Disease Progression; Humans; Levodopa; Male; Nerve Tissue Proteins; Nuclear Proteins; Repressor Proteins; Restless Legs Syndrome	2007
Differential loss of presynaptic dopaminergic markers in Parkinsonian monkeys. Cell transplantation, 2007, Volume: 16, Issue:3 Topics: Animals; Antiparkinson Agents; Aromatic-L-Amino-Acid Decarboxylases; Basal Ganglia; Biomarkers; Disease Progression; Dopamine; Dopamine Agents; Dopamine Plasma Membrane Transport Proteins; Humans; Levodopa; Male; Parkinsonian Disorders; Placebos; Presynaptic Terminals; Saimiri; Tyrosine 3-Monooxygenase; Vesicular Monoamine Transport Proteins	2007
Patterns of levodopa response in Parkinson's disease: a clinico-pathological study. Brain : a journal of neurology, 2007, Volume: 130, Issue:Pt 8 Topics: Accidental Falls; Adult; Age Factors; Age of Onset; Aged; Aged, 80 and over; Antiparkinson Agents; Cognition Disorders; Disease Progression; Female; Hallucinations; Humans; Levodopa; Lewy Bodies; Male; Middle Aged; Parkinson Disease; Retrospective Studies; Severity of Illness Index; Treatment Outcome	2007
Potential outcome measures and trial design issues for multiple system atrophy. Movement disorders : official journal of the Movement Disorder Society, 2007, Volume: 22, Issue:16 Topics: Aged; Antiparkinson Agents; Cerebellar Diseases; Clinical Trials as Topic; Disability Evaluation; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Multiple System Atrophy; Research Design; Risk Factors; Sample Size; Socioeconomic Factors; Treatment Outcome	2007
Disease progression, drug action and Parkinson's disease: why time cannot be ignored. European journal of clinical pharmacology, 2008, Volume: 64, Issue:2 Topics: Antiparkinson Agents; Clinical Trials as Topic; Disease Progression; Humans; Levodopa; Models, Biological; Parkinson Disease; Time Factors	2008
Clinical aspects of bowel symptoms in Parkinson's disease. Acta neurologica Scandinavica, 2008, Volume: 117, Issue:1 Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Anal Canal; Antiparkinson Agents; Autonomic Pathways; Central Nervous System; Comorbidity; Constipation; Disability Evaluation; Disease Progression; Enteric Nervous System; Fecal Incontinence; Female; Humans; Intestines; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Surveys and Questionnaires	2008
Excessive dopamine neuron loss in progressive supranuclear palsy. Movement disorders : official journal of the Movement Disorder Society, 2008, Mar-15, Volume: 23, Issue:4 Topics: Aged; Disease Progression; Dopamine; Dopamine Agonists; Female; Humans; Levodopa; Male; Nerve Degeneration; Neurons; Substantia Nigra; Supranuclear Palsy, Progressive	2008
Homozygous SCA 2 mutations changes phenotype and hastens progression. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-15, Volume: 23, Issue:5 Topics: Antiparkinson Agents; Ataxins; Dementia; Disease Progression; Dyskinesias; Female; Follow-Up Studies; Homozygote; Humans; Levodopa; Male; Mutation; Nerve Tissue Proteins; Ocular Motility Disorders; Parkinsonian Disorders; Phenotype; Psychotic Disorders; Spinocerebellar Degenerations	2008
Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease. Neuro-degenerative diseases, 2008, Volume: 5, Issue:3-4 Topics: Disease Progression; Duodenum; Female; Humans; Infusions, Parenteral; Levodopa; Male; Parkinson Disease; Prospective Studies; Quality of Life	2008
Clinical heterogeneity in newly diagnosed Parkinson's disease. Journal of neurology, 2008, Volume: 255, Issue:5 Topics: Adult; Age Distribution; Age of Onset; Aged; Aged, 80 and over; Anxiety Disorders; Cluster Analysis; Cohort Studies; Comorbidity; Depressive Disorder; Disability Evaluation; Disease Progression; Female; Humans; Immunity, Innate; Levodopa; Male; Middle Aged; Movement Disorders; Netherlands; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Quality of Life	2008
[Multi-infarct disorder presenting as corticobasal degeneration (DCB): vascular pseudo-corticobasal degeneration?]. Revue neurologique, 2007, Volume: 163, Issue:12 Topics: Aged; Antiparkinson Agents; Basal Ganglia; Cerebral Cortex; Dementia, Multi-Infarct; Diagnosis, Differential; Disease Progression; Drug Resistance; Electroencephalography; Epilepsies, Myoclonic; Female; Functional Laterality; Gait Apraxia; Humans; Hypertension; Levodopa; Magnetic Resonance Imaging; Middle Aged; Nerve Degeneration; Neurologic Examination; Parkinson Disease; Phenotype	2007
The evolution of disability in Parkinson disease. Movement disorders : official journal of the Movement Disorder Society, 2008, Apr-30, Volume: 23, Issue:6 Topics: Activities of Daily Living; Aged; Diagnosis, Differential; Disabled Persons; Disease Progression; Female; Gait Disorders, Neurologic; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Parkinson Disease; Self Care; Severity of Illness Index; Tremor	2008
Multiparity after an initial diagnosis of Parkinson's disease: a report on a rare case. Fertility and sterility, 2008, Volume: 90, Issue:5 Topics: Adult; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Live Birth; Natural Childbirth; Parity; Parkinson Disease; Pregnancy; Pregnancy Complications	2008
[Precoce survey: a new self-assessment patient card for early detection and management of Parkinson disease fluctuations]. Revue neurologique, 2008, Volume: 164, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aging; Antiparkinson Agents; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Parkinson Disease; Reproducibility of Results; Surveys and Questionnaires	2008
Changes in diagnosis with follow-up in an incident cohort of patients with parkinsonism. Journal of neurology, neurosurgery, and psychiatry, 2008, Volume: 79, Issue:11 Topics: Aged; Antiparkinson Agents; Brain; Diagnosis, Differential; Disease Progression; Female; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinsonian Disorders; Pilot Projects; Predictive Value of Tests; Severity of Illness Index; Surveys and Questionnaires; Tomography, X-Ray Computed	2008
Rate of motor response to oral levodopa and the clinical progression of Parkinson's disease. Neurology, 1996, Volume: 46, Issue:4 Topics: Administration, Oral; Adult; Aged; Antiparkinson Agents; Disease Progression; Drug Therapy, Combination; Female; Humans; Levodopa; Male; Middle Aged; Movement; Parkinson Disease; Reaction Time; Severity of Illness Index; Treatment Outcome	1996
The pattern electroretinogram in Parkinson's disease reveals lack of retinal spatial tuning. Electroencephalography and clinical neurophysiology, 1996, Volume: 100, Issue:1 Topics: Aged; Aged, 80 and over; Aging; Disease Progression; Electroretinography; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Reference Values; Retina; Space Perception; Time Perception; Visual Perception	1996
Treatment of Parkinson's disease: disagreements. Annals of neurology, 1997, Volume: 41, Issue:6 Topics: Disease Progression; Humans; Levodopa; Parkinson Disease; Selegiline	1997
High-frequency stimulation of the globus pallidus internalis in Parkinson's disease: a study of seven cases. Journal of neurosurgery, 1997, Volume: 87, Issue:4 Topics: Adult; Disease Progression; Dyskinesia, Drug-Induced; Electric Stimulation Therapy; Electrodes, Implanted; Follow-Up Studies; Gait; Globus Pallidus; Humans; Hypokinesia; Levodopa; Male; Middle Aged; Movement Disorders; Muscle Rigidity; Parkinson Disease; Speech Disorders; Stereotaxic Techniques; Thalamic Nuclei; Treatment Outcome; Tremor	1997
A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain research, 1997, Aug-22, Volume: 766, Issue:1-2 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Cell Count; Chronic Disease; Disease Models, Animal; Disease Progression; Dopamine Agents; Levodopa; Macaca fascicularis; Movement; Neurons; Parkinson Disease, Secondary; Tyrosine 3-Monooxygenase	1997
Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology, 1998, Volume: 50, Issue:2 Topics: Antiparkinson Agents; Apomorphine; Disease Progression; Humans; Levodopa; Motor Activity; Parkinson Disease	1998
Adverse reactions to levodopa: drug toxicity or progression of disease? Lancet (London, England), 1998, Mar-21, Volume: 351, Issue:9106 Topics: Antiparkinson Agents; Disease Progression; Humans; Levodopa; Parkinson Disease	1998
Clinical similarities of hereditary progressive/dopa responsive dystonia caused by different types of mutations in the GTP cyclohydrolase I gene. Journal of neurology, neurosurgery, and psychiatry, 1998, Volume: 64, Issue:4 Topics: Adolescent; Adult; Age of Onset; Case-Control Studies; Circadian Rhythm; Disease Progression; DNA; Dopamine Agents; Exons; Female; Genetic Carrier Screening; GTP Cyclohydrolase; Hereditary Sensory and Motor Neuropathy; Humans; Japan; Levodopa; Male; Middle Aged; Mutation; Pedigree; Sequence Analysis, DNA	1998
[Long chronic course of hemiparkinson-plus with l-dopa maintained response]. Revista de neurologia, 1998, Volume: 27, Issue:155 Topics: Aged; Antiparkinson Agents; Chronic Disease; Disease Progression; Dose-Response Relationship, Drug; Dystonia; Functional Laterality; Humans; Levodopa; Male; Parkinson Disease	1998
Slowly progressive L-DOPA nonresponsive pure akinesia due to nigropallidal degeneration: a clinicopathological case study. Journal of the neurological sciences, 1998, Dec-11, Volume: 161, Issue:2 Topics: Disease Progression; Dopamine Agents; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Movement Disorders; Neurodegenerative Diseases; Substantia Nigra; Treatment Failure	1998
A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease. Neurobiology of disease, 1999, Volume: 6, Issue:1 Topics: Aged; Antiparkinson Agents; Brain Chemistry; Chromatography, High Pressure Liquid; Disease Progression; Dopamine; Female; Humans; Hydroxyindoleacetic Acid; Levodopa; Male; Middle Aged; Parkinson Disease; Tyrosine	1999
L-dopa slows the progression of familial parkinsonism. Lancet (London, England), 1999, May-29, Volume: 353, Issue:9167 Topics: Adult; Antiparkinson Agents; Disease Progression; Humans; Levodopa; Middle Aged; Parkinson Disease; Survival Analysis	1999
Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antiparkinson Agents; Disease Progression; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prospective Studies; Time Factors	1999
The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 1999, Volume: 14, Issue:5 Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adrenergic Antagonists; Animals; Antiparkinson Agents; Brain; Callithrix; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesias; Female; Idazoxan; Levodopa; Male; Receptors, Adrenergic, alpha-2; Time Factors; Yohimbine	1999
Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): clinical implications of axonal spread. Journal of the neurological sciences, 1999, Oct-15, Volume: 168, Issue:2 Topics: Adolescent; Axons; Basal Ganglia; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Parkinson Disease, Secondary; Subacute Sclerosing Panencephalitis; Treatment Failure	1999
Parkinson's disease: therapeutic choices and timing decisions in patient management. Interview by Wayne Kuznar. Geriatrics, 1999, Volume: 54, Issue:10 Topics: Age Factors; Aged; Antiparkinson Agents; Benzophenones; Carbidopa; Disease Progression; Drug Administration Schedule; Electric Stimulation Therapy; Humans; Levodopa; Middle Aged; Nitrophenols; Parkinson Disease; Patient Selection; Selegiline; Time Factors; Tolcapone	1999
Amelioration of sensory limb discomfort of restless legs syndrome by pallidotomy. Annals of neurology, 1999, Volume: 46, Issue:5 Topics: Anticonvulsants; Carbidopa; Disease Progression; Follow-Up Studies; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Restless Legs Syndrome; Treatment Outcome	1999
Maximizing the benefit:risk ratio of levodopa therapy in Parkinson's disease. Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2 Topics: Antiparkinson Agents; Catechol O-Methyltransferase Inhibitors; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Dyskinesias; Humans; Levodopa; Odds Ratio; Parkinson Disease	1999
Successful orchestration of antiparkinsonian pharmacotherapy. Pharmacotherapy, 1999, Volume: 19, Issue:11 Pt 2 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Carbidopa; Comorbidity; Disease Progression; Drug Combinations; Dyskinesias; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Pharmacists	1999
Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data. Journal of the neurological sciences, 1999, Nov-30, Volume: 170, Issue:2 Topics: Age Factors; Age of Onset; Aged; Antiparkinson Agents; Bromocriptine; Disease Progression; Erythrocytes; Humans; Hydroxyl Radical; Levodopa; Middle Aged; Multiple System Atrophy; Parkinson Disease; Pergolide; Severity of Illness Index; Statistics as Topic; Superoxide Dismutase; Time Factors	1999
Bilateral intracaudate cografting of fetal ventral mesencephalon and striatum in advanced Parkinson's disease. Transplantation proceedings, 1999, Volume: 31, Issue:8 Topics: Adult; Aged; Antiparkinson Agents; Brain; Brain Tissue Transplantation; Corpus Striatum; Disease Progression; Fetal Tissue Transplantation; Follow-Up Studies; Humans; Levodopa; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Motor Activity; Parkinson Disease; Time Factors; Tomography, X-Ray Computed	1999
The effect of pregnancy in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:1 Topics: Adult; Antiparkinson Agents; Carbidopa; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Follow-Up Studies; Humans; Infant, Newborn; Levodopa; Neurologic Examination; Parkinson Disease; Pregnancy; Pregnancy Complications; Quality of Life	2000
Levodopa toxicity in Parkinson disease: reality or myth? Reality--practice patterns should change. Archives of neurology, 2000, Volume: 57, Issue:3 Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Research Design; Treatment Outcome	2000
Is levodopa toxic? Archives of neurology, 2000, Volume: 57, Issue:3 Topics: Antiparkinson Agents; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Humans; Levodopa; Parkinson Disease; Time Factors	2000
Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2000, Volume: 107, Issue:1 Topics: Age Distribution; Age of Onset; Aged; Antiparkinson Agents; Dementia; Depression; Disease Progression; Female; Humans; Levodopa; Linear Models; Male; Middle Aged; Parkinson Disease; Prevalence; Psychotic Disorders; Risk Factors	2000
Differential progression of motor impairment in levodopa-treated Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2000, Volume: 15, Issue:3 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Longitudinal Studies; Male; Motor Skills; Neurologic Examination; Parkinson Disease	2000
Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain : a journal of neurology, 2000, Volume: 123 ( Pt 11) Topics: Age of Onset; Aged; Disease Progression; Dopamine Agonists; Dyskinesia, Drug-Induced; Humans; Levodopa; Outpatients; Parkinson Disease; Prevalence; Quality of Life; Regression Analysis; Treatment Outcome	2000
Freezing of gait in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2001, Volume: 108, Issue:1 Topics: Adult; Age of Onset; Amantadine; Antiparkinson Agents; Disease Progression; Dopamine Agonists; Female; Freezing; Gait Disorders, Neurologic; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Prevalence; Regression Analysis; Retrospective Studies; Selegiline	2001
Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism & related disorders, 2001, Volume: 8, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiparkinson Agents; Cadaver; Child; Disease Progression; Dystonia; Female; Humans; Levodopa; Longevity; Male; Middle Aged; Parkinsonian Disorders; Retrospective Studies; Substantia Nigra; Survival Analysis; Tremor	2001
Acceleration of HIV dementia with methamphetamine and cocaine. Journal of neurovirology, 2001, Volume: 7, Issue:1 Topics: Adult; AIDS Dementia Complex; Amphetamine-Related Disorders; Antiretroviral Therapy, Highly Active; Blood-Brain Barrier; Brain; Cholinergic Antagonists; Cocaine-Related Disorders; Disease Progression; Humans; Levodopa; Magnetic Resonance Imaging; Male; Methamphetamine; Movement Disorders	2001
Pharmacodynamic modeling of oral levodopa in Parkinson's disease. Annals of neurology, 2001, Volume: 50, Issue:5 Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Levodopa; Parkinson Disease; Predictive Value of Tests; Psychomotor Performance; Raclopride; Tomography, Emission-Computed	2001
Comparison of natural histories of progressive supranuclear palsy and multiple system atrophy. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2001, Volume: 22, Issue:3 Topics: Aged; Antiparkinson Agents; Disability Evaluation; Disease Progression; Female; Humans; Levodopa; Life Tables; Male; Middle Aged; Multiple System Atrophy; Supranuclear Palsy, Progressive	2001
Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology, 2001, Dec-11, Volume: 57, Issue:11 Topics: Aged; Dementia; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Female; Hallucinations; Humans; Levodopa; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Parkinson Disease; Prospective Studies; Psychiatric Status Rating Scales; Risk Factors	2001
Phenotypic characterisation of autosomal recessive PARK6-linked parkinsonism in three unrelated Italian families. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6 Topics: Adult; Age of Onset; Aged; Chromosomes, Human, Pair 1; Diagnosis, Differential; Disease Progression; Dyskinesia, Drug-Induced; Female; Functional Laterality; Gait Disorders, Neurologic; Genes, Recessive; Haplotypes; Humans; Italy; Levodopa; Lod Score; Male; Middle Aged; Parkinsonian Disorders; Pedigree; Phenotype; Syndrome; Tremor; Videotape Recording	2001
Gastric emptying time and gastric motility in patients with Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society, 2001, Volume: 16, Issue:6 Topics: Aged; Antiparkinson Agents; Case-Control Studies; Disease Progression; Female; Gastric Emptying; Gastrointestinal Motility; Humans; Levodopa; Male; Middle Aged; Parkinson Disease; Radiopharmaceuticals; Severity of Illness Index; Technetium Tc 99m Aggregated Albumin; Tomography, Emission-Computed	2001
[Relation between autonomic dysfunction and progression of Parkinson's disease]. Rinsho shinkeigaku = Clinical neurology, 2001, Volume: 41, Issue:6 Topics: Adult; Aged; Autonomic Nervous System Diseases; Baroreflex; Disease Progression; Humans; Levodopa; Middle Aged; Parkinson Disease; Valsalva Maneuver	2001
Parkinson disease neuropathology: later-developing dementia and loss of the levodopa response. Archives of neurology, 2002, Volume: 59, Issue:1 Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Brain; Disease Progression; Female; Humans; Incidence; Levodopa; Lewy Bodies; Lewy Body Disease; Male; Middle Aged; Neurofibrillary Tangles; Parkinson Disease; Plaque, Amyloid; Prevalence; Retrospective Studies	2002
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease. Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:1 Topics: 3,4-Dihydroxyphenylacetic Acid; Aged; Aged, 80 and over; Antiparkinson Agents; Benzophenones; Catechol O-Methyltransferase Inhibitors; Dihydroxyphenylalanine; Disease Progression; Dose-Response Relationship, Drug; Female; Homovanillic Acid; Humans; Levodopa; Male; Middle Aged; Nitrophenols; Parkinson Disease; Tolcapone; Tyrosine	2002
Is it time to abandon functional imaging in the study of neuroprotection? Movement disorders : official journal of the Movement Disorder Society, 2002, Volume: 17, Issue:2 Topics: Antiparkinson Agents; Brain; Clinical Trials as Topic; Disease Progression; Humans; Indoles; Levodopa; Parkinson Disease; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2002
A novel grading scale for striatonigral degeneration (multiple system atrophy). Journal of neural transmission (Vienna, Austria : 1996), 2002, Volume: 109, Issue:3 Topics: Adult; Aged; Caudate Nucleus; Disease Progression; Female; Gliosis; Globus Pallidus; Humans; Levodopa; Male; Middle Aged; Neurons; Prospective Studies; Putamen; Striatonigral Degeneration; Substantia Nigra	2002
The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease. Journal of neurochemistry, 2002, Volume: 81, Issue:1 Topics: Aging; Animals; Behavior, Animal; Brain; Brain Chemistry; Central Nervous System Stimulants; Cocaine; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Disease Progression; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Female; Glucose Tolerance Test; Huntington Disease; Levodopa; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Transgenic; Motor Activity; Spatial Behavior; Survival Rate	2002